$ 2023 Q1 10-K

Concept	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$31.51M	$31.51M
YoY Change	-30.61%	-30.61%
Cash & Equivalents	$30.40M	$30.44M
Short-Term Investments	$1.071M	$1.071M
Other Short-Term Assets	$22.90M	$22.90M
YoY Change	-14.11%	-14.11%
Inventory	$42.65M	$42.65M
Prepaid Expenses
Receivables	$27.87M	$27.87M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$124.9M	$124.9M
YoY Change	-6.35%	-6.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.824M	$6.043M
YoY Change	-64.79%	-82.34%
Goodwill	$0.00
YoY Change
Intangibles	$72.11M
YoY Change	0.3%
Long-Term Investments
YoY Change
Other Assets	$804.0K	$971.0K
YoY Change	-26.03%	-96.52%
Total Long-Term Assets	$79.13M	$79.13M
YoY Change	-40.97%	-40.97%
TOTAL ASSETS
Total Short-Term Assets	$124.9M	$124.9M
Total Long-Term Assets	$79.13M	$79.13M
Total Assets	$204.1M	$204.1M
YoY Change	-23.7%	-23.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$33.68M	$33.68M
YoY Change	131.99%	101.18%
Accrued Expenses	$35.37M	$32.88M
YoY Change	48.02%	47.66%
Deferred Revenue	$2.823M
YoY Change	0.86%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$37.13M	$37.13M
YoY Change	-20.81%	-20.81%
Total Short-Term Liabilities	$114.9M	$114.9M
YoY Change	19.61%	19.61%
LONG-TERM LIABILITIES
Long-Term Debt	$86.84M	$86.84M
YoY Change	-16.06%	-16.06%
Other Long-Term Liabilities	$2.731M	$24.77M
YoY Change	-10.34%	-21.97%
Total Long-Term Liabilities	$2.731M	$111.6M
YoY Change	-10.34%	-17.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$114.9M	$114.9M
Total Long-Term Liabilities	$2.731M	$111.6M
Total Liabilities	$228.2M	$210.6M
YoY Change	-2.04%	-2.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.017B
YoY Change	11.32%
Common Stock	$1.017B
YoY Change	4.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$7.757M
YoY Change	3.63%
Treasury Stock Shares	$84.93K
Shareholders Equity	-$6.506M	-$6.506M
YoY Change
Total Liabilities & Shareholders Equity	$204.1M	$204.1M
YoY Change	-23.7%	-23.7%

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	us-gaap	Impairment Of Intangible Asset Indefinite Lived Excluding Goodwill Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#GoodwillAndIntangibleAssetImpairment
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.athenex.com/20221231#LongTermDebtAndFinanceLeaseObligationsNonCurrent
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#GoodwillAndIntangibleAssetImpairment
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001300699
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	1071000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.athenex.com/20221231#LongTermDebtAndFinanceLeaseObligationsNonCurrent
CY2022	us-gaap	Discontinued Operation Gain Loss On Disposal Statement Of Income Or Comprehensive Income Extensible Enumeration DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38112
CY2022	dei	Entity Registrant Name EntityRegistrantName	ATHENEX, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	43-1985966
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1001 Main Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Buffalo
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	14203
CY2022	dei	City Area Code CityAreaCode	716
CY2022	dei	Local Phone Number LocalPhoneNumber	427-2950
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	ATNX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	32500000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8663209
CY2022	dei	Auditor Firm AuditorFirmId	34
CY2022	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2022	dei	Auditor Location AuditorLocation	Williamsville, New York
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30437000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35202000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5183000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	16500000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	10207000
CY2022Q4	atnx	Chargebacks And Other Deductions Current ChargebacksAndOtherDeductionsCurrent	29470000
CY2021Q4	atnx	Chargebacks And Other Deductions Current ChargebacksAndOtherDeductionsCurrent	22869000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	9676000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	9069000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27865000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22778000
CY2022Q4	us-gaap	Inventory Net InventoryNet	42654000
CY2021Q4	us-gaap	Inventory Net InventoryNet	23068000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10578000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5337000
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	7141000
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	20303000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	124929000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	133395000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1824000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3191000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	72112000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	71896000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4219000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5670000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	804000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1071000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	167000
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	52225000
CY2022Q4	us-gaap	Assets Assets	204055000
CY2021Q4	us-gaap	Assets Assets	267448000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	33682000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12485000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	35365000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23678000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2087000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2478000
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	37127000
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	46076000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	900000
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	5718000
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	11331000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	114879000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	96048000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3051000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4494000
CY2022Q4	atnx	Long Term Debt And Finance Lease Obligations Non Current LongTermDebtAndFinanceLeaseObligationsNonCurrent	93000
CY2021Q4	atnx	Long Term Debt And Finance Lease Obligations Non Current LongTermDebtAndFinanceLeaseObligationsNonCurrent	95607000
CY2022Q4	atnx	Royalty Financing Liability Noncurrent RoyaltyFinancingLiabilityNoncurrent	86745000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1751000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1751000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	18986000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	24076000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2731000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3046000
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	7974000
CY2022Q4	us-gaap	Liabilities Liabilities	228236000
CY2021Q4	us-gaap	Liabilities Liabilities	232996000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12500000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8711696
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5590149
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8626769
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5506503
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	9000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1017194000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	972509000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	887000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-487000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1016839000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-913412000
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	84928
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	83646
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	7757000
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	7485000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6506000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	51131000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-17675000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-16679000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24181000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34452000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	204055000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	267448000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	102821000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	95369000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	76118000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	62892000
CY2022	us-gaap	Gross Profit GrossProfit	26703000
CY2021	us-gaap	Gross Profit GrossProfit	32477000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51758000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77668000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	44880000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64230000
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	79000
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	41011000
CY2022	us-gaap	Operating Expenses OperatingExpenses	96717000
CY2021	us-gaap	Operating Expenses OperatingExpenses	182909000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-70014000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-150432000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	363000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	128000
CY2022	us-gaap	Interest Expense InterestExpense	25843000
CY2021	us-gaap	Interest Expense InterestExpense	20654000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3134000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-98628000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-170958000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	347000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10604000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-98975000
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-160354000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-5448000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-41682000
CY2022	us-gaap	Profit Loss ProfitLoss	-104423000
CY2021	us-gaap	Profit Loss ProfitLoss	-202036000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-996000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2268000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-103427000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-199768000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	465000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	506000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	909000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	141000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102053000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-199121000
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-14.98
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-14.98
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-30.42
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-30.42
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.83
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.83
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-8.02
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-8.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-15.81
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-15.81
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-38.44
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-38.44
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6541068
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6541068
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5196923
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5196923
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	165348000
CY2021	atnx	Stock Issuance Costs StockIssuanceCosts	35000
CY2021	atnx	Sale Of Common Stock Through Atm And Employee Stock Purchase Plan Value SaleOfCommonStockThroughAtmAndEmployeeStockPurchasePlanValue	1342000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8591000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	616000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1579000
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	79000
CY2021	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	16000
CY2021	us-gaap	Profit Loss ProfitLoss	-202036000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	647000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34452000
CY2022	atnx	Stock Issuance Costs StockIssuanceCosts	291000
CY2022	atnx	Sale Of Common Stock Through Atm Value SaleOfCommonStockThroughAtmValue	9395000
CY2022	atnx	Sale Of Common Stock Through Espp Value SaleOfCommonStockThroughEsppValue	545000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	8306000
CY2022	atnx	Sale Of Pre Funded Warrants SaleOfPreFundedWarrants	2343000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5576000
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	750000
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	272000
CY2022	us-gaap	Profit Loss ProfitLoss	-104423000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1374000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24181000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-98975000
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-160354000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-5448000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-41682000
CY2022	atnx	Depreciation And Amortization Continuing Operations DepreciationAndAmortizationContinuingOperations	2322000
CY2021	atnx	Depreciation And Amortization Continuing Operations DepreciationAndAmortizationContinuingOperations	3138000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6326000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	9207000
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	79000
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	41011000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-4190000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4237000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	134000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-456000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4362000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2939000
CY2022	atnx	Change In Fair Value Of Royalty Financing Liability ChangeInFairValueOfRoyaltyFinancingLiability	10240000
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-442000
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	331000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3134000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-648000
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-10848000
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	5221000
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2752000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-656000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3272000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19586000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	122000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	35929000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-19385000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-64348000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-129796000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	417000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	474000
CY2022	atnx	Payments For Licenses PaymentsForLicenses	1643000
CY2021	atnx	Payments For Licenses PaymentsForLicenses	2137000
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1425000
CY2021	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	101000
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	9087000
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	68672000
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	18683000
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	197608000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	7536000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	127851000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	29177000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1343000
CY2022	atnx	Proceeds From Issuance Of Royalty Financing Liability ProceedsFromIssuanceOfRoyaltyFinancingLiability	81500000
CY2022	atnx	Proceeds From Issuance Of Warrants And Pre Funded Warrants ProceedsFromIssuanceOfWarrantsAndPreFundedWarrants	11050000
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1464000
CY2022	atnx	Payments For Issuance Of Warrants And Pre Funded Warrants PaymentsForIssuanceOfWarrantsAndPreFundedWarrants	684000
CY2022	atnx	Payments For Issuance Of Royalty Financing Liability PaymentsForIssuanceOfRoyaltyFinancingLiability	4982000
CY2022	atnx	Costs Incurred Related To The Prepayment Of Debt CostsIncurredRelatedToThePrepaymentOfDebt	6515000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1579000
CY2022	atnx	Payments For Repurchase Of Treasury Stock PaymentsForRepurchaseOfTreasuryStock	272000
CY2021	atnx	Payments For Repurchase Of Treasury Stock PaymentsForRepurchaseOfTreasuryStock	79000
CY2022	atnx	Repayment Of Finance Lease Obligations And Long Term Debt And Royalty Financing Liability RepaymentOfFinanceLeaseObligationsAndLongTermDebtAndRoyaltyFinancingLiability	105439000
CY2021	atnx	Repayment Of Finance Lease Obligations And Long Term Debt And Royalty Financing Liability RepaymentOfFinanceLeaseObligationsAndLongTermDebtAndRoyaltyFinancingLiability	106000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2371000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2737000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-54441000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	792000
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-10666000
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-12585000
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	50366000
CY2021	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-22866000
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-807000
CY2021	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-274000
CY2022	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	38893000
CY2021	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-35725000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	51702000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86087000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-534000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	548000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	35620000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	51702000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	11088000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	20336000
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	586000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	108000
CY2022	atnx	Accrued Purchases Of Property And Equipment From Continuing Operations AccruedPurchasesOfPropertyAndEquipmentFromContinuingOperations	21000
CY2021	atnx	Accrued Purchases Of Property And Equipment From Continuing Operations AccruedPurchasesOfPropertyAndEquipmentFromContinuingOperations	246000
CY2021	atnx	Accrued Purchases Of Property And Equipment From Discontinued Operations AccruedPurchasesOfPropertyAndEquipmentFromDiscontinuedOperations	1679000
CY2022	atnx	Modification Of Warrants ModificationOfWarrants	283000
CY2022	atnx	Accrued Purchases Of Licenses AccruedPurchasesOfLicenses	1138000
CY2021	atnx	Accrued Purchases Of Licenses AccruedPurchasesOfLicenses	1250000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	146000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	203000
CY2022	atnx	Right Of Use Assets Derecognized From Modification Of Operating Lease Obligations RightOfUseAssetsDerecognizedFromModificationOfOperatingLeaseObligations	128000
CY2021	atnx	Right Of Use Assets Derecognized From Modification Of Operating Lease Obligations RightOfUseAssetsDerecognizedFromModificationOfOperatingLeaseObligations	114000
CY2021	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	52786000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">COMPANY AND NATURE OF BUSINESS </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Description of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Athenex, Inc. (the “Company” or “Athenex”), originally under the name Kinex Pharmaceuticals LLC (“Kinex”), formed in November 2003, commenced operations on February 5, 2004, and operated as a limited liability company until it was incorporated in the State of Delaware under the name Kinex Pharmaceuticals, Inc. on December 31, 2012. The Company changed its name to Athenex, Inc. on August 26, 2015.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Athenex is a biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by creating more effective, safer, and accessible treatments. The Company has assembled a strong and experienced leadership team and has established operations across the pharmaceutical value chain to execute our goal of becoming a leader in bringing innovative cancer treatments to the market and improving health outcomes.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is organized around </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> operating segments: (1) its Oncology Innovation Platform, dedicated to the research and development of our proprietary drugs; and (2) its Commercial Platform, focused on the sales and marketing of our specialty drugs and the market development of our proprietary drugs. The Company’s current clinical pipeline in the Oncology Innovation Platform is derived mainly from the following core technologies: (a) Cell Therapy, based on natural killer T ("NKT") cells, and (b) Orascovery, based on a P-glycoprotein pump inhibitor. The Company previously had a third operating segment, the Global Supply Chain Platform, focused on the current Good Manufacturing Practices ("cGMP") manufacturing and supply of active pharmaceutical ingredients and 503B sterile compounded pharmaceutical products. The components within this operating segment were discontinued during 2022 and are reported as discontinued operations. Refer to Note 3 – </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Discontinued Operations </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">for additional information.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities. The Company also conducts commercial sales of specialty products through its wholly owned subsidiary, Athenex Pharmaceutical Division (“APD”).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Going Concern</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">These consolidated financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company has incurred operating losses since its inception and, as a result, as of December 31, 2022 and 2021 had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,016.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">913.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, respectively. As of December 31, 2022, the Company had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">30.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, restricted cash of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, and short-term investments of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million. </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company projects insufficient liquidity to fund its operations through the next </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">twelve months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> beyond the date of the issuance of these consolidated financial statements. This condition raises substantial doubt about the Company’s ability to continue as a going concern. </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:"Times New Roman", serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is in compliance with the minimum liquidity and minimum revenue financial covenants in the Senior Credit Agreement as of December 31, 2022. However, the Company received notices of certain alleged defaults and reservations of rights related to the Senior Credit Agreement, as described in Note 12 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Debt and Lease Obligations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, and is forecasting noncompliance with the minimum liquidity covenant and minimum revenue covenant included within the Senior Credit Agreement during the twelve month period subsequent to the date of this filing. Pursuant to ASC 205-40-50, the Company’s forecast and analysis herein does not reflect management’s plans that are outside of the Company’s control as described below. Violation of any covenant under the Senior Credit Agreement provides the lenders with the option to accelerate the maturity of the amounts due under the Senior Credit Agreement, which was $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">44.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million as of December 31, 2022. Should the lenders accelerate the maturity of the amounts due under the Senior Credit Agreement, the Company would not have sufficient cash on hand or available liquidity to repay the outstanding debt. These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern.</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In response to these conditions, management’s plans include seeking additional funding through asset monetization, seeking funding through alternative means, and raising capital. There can be no assurances, however, that the Company will be able to monetize assets or obtain additional funding on favorable terms, or at all. Because management’s plans have not yet been finalized and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">are not within the Company’s control, such plans cannot be considered probable of being achieved. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Other Significant Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In February 2021, the Company received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s New Drug Application (“NDA”) for oral paclitaxel and encequidar (“Oral Paclitaxel”) for the treatment of metastatic breast cancer (“mBC”), indicating that the application is not ready for approval in its present form. In the CRL, the FDA indicated its concern of safety risk to patients in terms of an increase in neutropenia-related sequelae on the Oral Paclitaxel arm compared with the IV paclitaxel arm in the Phase III study. The FDA also expressed concerns regarding the uncertainty over the results of the primary endpoint of objective response rate at week 19 conducted by blinded independent central review. During the second quarter of 2021, the Company held a Type A meeting with the FDA, where it provided additional analyses, including overall survival data on patient subgroups, to provide a more comprehensive summary of the risk/benefit assessment. In October 2021, after careful consideration of the FDA’s feedback, the Company determined to redeploy its resources to focus on the cell therapy platform and ongoing studies of Oral Paclitaxel.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is subject to a number of risks, including, but not limited to, the lack of available capital; the possible delisting of our common stock from Nasdaq; possible failure of preclinical testing or clinical trials; inability to obtain regulatory approval of product candidates; competitors developing new technological innovations; potential interruptions in the manufacturing and commercial supply operations; unsuccessful commercialization strategy and launch plans for its proprietary drug candidates; risks inherent in litigation, including purported class actions; market acceptance of the Company’s products; and protection of proprietary technology. If the Company or its partners do not successfully commercialize any of the Company’s product candidates, it will be unable to generate sufficient revenue and might not, if ever, achieve profitability and positive cash flow.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Recent Financing Activity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Public Offering of Common Stock and Warrants</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In August 2022, the Company completed an underwritten public offering in which it sold </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,766,667</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of common stock, common warrants to purchase up to </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">20.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share, and pre-funded warrants to purchase up to </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">233,334</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.02</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share. The shares of common stock, together with the common warrants, were sold at $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share and accompanying common warrant, and the pre-funded warrants, together with the common warrants, were sold at $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14.98</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per pre-funded warrant and accompanying common warrant. The common and pre-funded warrants were exercisable immediately and will expire </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> from the date of issuance. The Company received net proceeds of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">28.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, after deducting discounts, commissions, and offering expenses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">At-the-market offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On August 20, 2021, the Company entered into a sales agreement (the “Sales Agreement”) with SVB Leerink LLC, in connection with the offer and sale of up to $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">100,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> of shares of the Company’s common stock, par value $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share (“ATM Shares”). The ATM Shares to be offered and sold under the Sales Agreement will be issued and sold pursuant to a registration statement on Form S-3 (File No. 333-258185) that became effective on August 12, 2021. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company sold </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,263,251</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of its common stock for an average price of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share under the Sales Agreement. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company sold </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">38,142</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of its common stock for an average price of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">29.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share under the Sales Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Sale of U.S. and European tirbanibulin royalty and milestone interests</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On June 21, 2022, the Company and ATNX SPV, LLC, its newly-formed subsidiary (the "SPV"), entered into a Revenue Interest Purchase Agreement (the “RIPA”) with affiliates of Sagard Healthcare Partners (“Sagard”) and funds managed by Oaktree (together with Sagard, the “Purchasers”), for the sale of revenues from U.S. and European royalty and milestone interests in Klisyri® (tirbanibulin) for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">85.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million (“Purchase Price”). On June 29, 2022, the Purchasers paid the Company the Purchase Price. Of the total Purchase Price, $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million was placed into escrow to be paid to the Company upon the satisfaction of certain manufacture and supply milestones for Klisyri prior to December 31, 2025, $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million was used to pay for transaction expenses, $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">56.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million was used to pay down principal, interest, and fees on the Company's Senior Credit Agreement with Oaktree, and $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million was deposited and held in a segregated account of the Company (the “Segregated Funds”). The Segregated Funds were released to the Company upon the underwritten public offering in August 2022 and $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million of the amount placed in escrow was released to the Company upon completion of an escrow release trigger milestone in September 2022. The $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.5</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">of Segregated Funds and the remaining proceeds of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million were available for the Company's operations. Refer to Note 12 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Debt and Lease Obligations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> for additional information.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In connection with this transaction, the Company formed the SPV and contributed its interest in the License and Development Agreement with Almirall S.A. relating to Klisyri (the “License Agreement”) and certain related assets to the SPV. Oaktree and Sagard each own a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% equity interest in the SPV. Pursuant to the RIPA, the SPV will sell its right to the cash received in respect of certain royalties and certain milestone interests under the License Agreement to the Purchasers. The SPV will retain the right to receive </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of certain of the milestone interests under the License Agreement, equal to $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">155.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million in the aggregate if those milestones are achieved, and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the royalties paid under the License Agreement for sales of Klisyri once net sales of Klisyri exceed a certain dollar amount. Under its operating agreement, the SPV will be governed by a five-member board of directors to which the Company will appoint three directors, Oaktree will appoint one director, and Sagard will appoint one director.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Senior Secured Loan Agreement and Detachable Warrants</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On June 19, 2020, the Company entered into a senior secured loan agreement and related security agreements (the “Senior Credit Agreement”) with Oaktree to borrow up to $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">225.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million in </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">five</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> tranches with a maturity date of </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">June 19, 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, bearing interest at a fixed annual rate of </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%. The first tranche of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million was drawn by the Company prior to June 30, 2020, with the proceeds used in part to repay in full the outstanding loan and fees under the credit agreement with Perceptive Advisors LLC and its affiliates. The second and third tranches of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million each were drawn by the Company prior to December 31, 2020. The additional debt tranches amounting to an aggregate of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million were subject to the approval Oral Paclitaxel in the treatment of mBC, and therefore, became unavailable to the Company when it decided to no longer pursue regulatory approval in the U.S. The Company was required to make quarterly interest-only payments until June 19, 2022, after which the Company is required to make quarterly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity. The loan agreement contains specified financial maintenance covenants. The Company was in compliance with such covenants as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In connection with the Senior Credit Agreement, the Company granted warrants to Oaktree to purchase an aggregate of up to </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">45,420</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of the Company’s common stock at an initial purchase price of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">252.60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share. This transaction was accounted for as a detachable warrant at its fair value, using the relative fair value method, which is based on a number of unobservable inputs, and is recorded as an increase to additional paid-in-capital on the consolidated statement of stockholders’ equity. The fair value of the warrants was reflected as a discount to the term loan and amortized over the life of the term loan.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On January 19, 2022, the Company entered into an amendment to the Senior Credit Agreement with Oaktree (the “Third Amendment”). The Third Amendment also amended the warrants held by Oaktree and Sagard that were issued on </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">June 19, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">August 4, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. The Third Amendment became effective on February 14, 2022, upon the closing of the Company’s sale of its leasehold interest in the manufacturing facility in Dunkirk, New York and certain other related assets (the “Dunkirk Transaction,” see Note 3 - Discontinued Operations). The Third Amendment required the Company to make a mandatory prepayment of principal to Oaktree equal to </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">62.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the cash proceeds of the Dunkirk Transaction. The Company was also required to pay (i) accrued and unpaid interest and (ii) a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% fee, allocated as a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% Exit Fee and a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% Prepayment Fee (each as defined in the Senior Credit Agreement), on the principal amount being repaid. The Company was required to pay Oaktree an amendment fee of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million and certain related expenses upon the closing of the Dunkirk Transaction. The Third Amendment required the Company to make an additional mandatory prepayment of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million in principal plus the costs and fees described above by June 14, 2022, within 120 days of the closing of the Dunkirk Transaction. Consistent with the Company’s decision to not pursue regulatory approval for Oral Paclitaxel monotherapy for the treatment of mBC in the United States, the Third Amendment reduced to zero the amount of the last </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> tranches of borrowing that had been available under the Senior Credit Agreement upon the achievement of commercial milestones. The warrants were amended to change the exercise price to be paid per share upon exercise of the warrants. The original exercise price of the warrants was $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">252.60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share; </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the shares underlying the warrants were repriced to $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">22.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share under the Third Amendment. The Dunkirk Transaction closed on February 14, 2022. The Company received proceeds of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">40.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million and used these proceeds to repay $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">27.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, inclusive of principal, fees, and accrued interest, of the Senior Credit Agreement with Oaktree according to the terms of the Third Amendment. During June 2022, the Company made the additional prepayment under the Third Amendment in the aggregate amount of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, inclusive of principal, fees, and accrued interest, as provided in the Fourth Amendment, described below.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In June 2022, the Company entered into additional amendments to the Senior Credit Agreement with Oaktree (the "Fourth Amendment" and the "Fifth Amendment" or the "Amendments"), in connection with the execution of the RIPA with Sagard and Oaktree. Under the Fourth Amendment, Oaktree permitted the Company to pay $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million in principal amount due pursuant to the Third Amendment on the closing date of the RIPA. Under the Fifth Amendment, the Company agreed to make an additional prepayment of principal to Oaktree of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million on or before July 1, 2022. The Company was also required to pay (i) accrued and unpaid interest and (ii) a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% fee, allocated as a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% Exit Fee and a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% Prepayment Fee (each as defined in the Senior Credit Agreement), on the principal amount being repaid pursuant to the Amendments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Fourth Amendment also amended the warrants held by Oaktree and Sagard that were issued on </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">June 19, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">August 4, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, as previously amended on January 19, 2022. The warrants were amended to change the exercise price to be paid per share upon exercise of the warrants. The original exercise price of the warrants was $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">252.60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">share. The Third Amendment had reduced the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">exercise </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">price of </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the shares underlying the Warrants to $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">22.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share, with the remaining </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% exercisable at $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">252.60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share. The Fourth Amendment reduced the exercise price of all of the warrants to $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In August 2022, the Company entered into the Sixth Amendment to the Senior Credit Agreement with Oaktree (the "Sixth Amendment"). The Sixth Amendment released the $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million of Segregated Funds to the Company and required the Company to prepay an additional $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million of the Senior Credit Agreement. The Company was also required to pay (i) accrued and unpaid interest and (ii) a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% fee, allocated as a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% Exit Fee and a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% Prepayment Fee (each as defined in the Senior Credit Agreement), on the principal amount being repaid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In early March 2023, the Company received notices of certain alleged defaults and reservations of rights from Oaktree. The alleged defaults relate to (i) the Company exceeding the $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million threshold for incurring additional indebtedness by having accounts payable owed to counterparties overdue by more than 90 days, (ii) the Company’s obligation to provide notice to Oaktree related to the foregoing, and (iii) the Company’s obligation to provide notice to Oaktree regarding the recent reverse stock split. Upon the occurrence of an Event of Default, Oaktree has the right to accelerate all amounts outstanding under the Senior Credit Agreement, in addition to other remedies available to it as a secured creditor of ours. If Oaktree accelerates the maturity of the indebtedness under the Senior Credit Agreement, the Company does not have sufficient capital available to pay the amounts due on a timely basis, if at all, and there is no guarantee that the Company would be able to repay, refinance or restructure the payments due under the Senior Credit Agreement. The Company responded to Oaktree, which included grounds upon which the Company disputes each of the alleged defaults. The Company has not reached a mutual agreement with Oaktree on this matter, and given the Company is in receipt of the notices of default and reservation of rights, which could result in payment to Oaktree on demand, the amounts due and outstanding to Oaktree are presented as a current obligation of the Company.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company's outstanding principal on the Senior Credit Agreement with Oaktree amounted to $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">44.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">150.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, respectively. Refer to Note 12 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Debt and Lease Obligations </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">for additional information.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On February 15, 2023, the Company effected a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="-sec-ix-hidden:F_ca377661-bb17-4c65-a79a-7bc106e7887c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">20</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">:1 reverse stock split of its common stock in order to regain compliance with Nasdaq's continued listing requirements.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> All share and per share amounts, and exercise prices of stock options, warrants, and pre-funded warrants, if applicable, in the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split. Refer to Note 21 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Subsequent Events </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">for additional information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1016800000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-913400000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30400000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	5200000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	1100000
CY2022	us-gaap	Substantial Doubt About Going Concern Conditions Or Events SubstantialDoubtAboutGoingConcernConditionsOrEvents	The Company projects insufficient liquidity to fund its operations through the next twelve months beyond the date of the issuance of these consolidated financial statements. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company is in compliance with the minimum liquidity and minimum revenue financial covenants in the Senior Credit Agreement as of December 31, 2022. However, the Company received notices of certain alleged defaults and reservations of rights related to the Senior Credit Agreement, as described in Note 12 - Debt and Lease Obligations, and is forecasting noncompliance with the minimum liquidity covenant and minimum revenue covenant included within the Senior Credit Agreement during the twelve month period subsequent to the date of this filing. Pursuant to ASC 205-40-50, the Company’s forecast and analysis herein does not reflect management’s plans that are outside of the Company’s control as described below. Violation of any covenant under the Senior Credit Agreement provides the lenders with the option to accelerate the maturity of the amounts due under the Senior Credit Agreement, which was $44.7 million as of December 31, 2022. Should the lenders accelerate the maturity of the amounts due under the Senior Credit Agreement, the Company would not have sufficient cash on hand or available liquidity to repay the outstanding debt. These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern.
CY2022	us-gaap	Substantial Doubt About Going Concern Within One Year SubstantialDoubtAboutGoingConcernWithinOneYear	true
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	19305000
CY2022	atnx	Business Combination Measurement Period Adjustments Increase In In Process Research And Development BusinessCombinationMeasurementPeriodAdjustmentsIncreaseInInProcessResearchAndDevelopment	1400000
	atnx	Business Combination Measurement Period Adjustments Decrease In Deferred Tax Liability BusinessCombinationMeasurementPeriodAdjustmentsDecreaseInDeferredTaxLiability	200000
	atnx	Business Combination Measurement Period Adjustments Decrease In Goodwill BusinessCombinationMeasurementPeriodAdjustmentsDecreaseInGoodwill	1600000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in clinical research accruals, chargebacks, measurement of acquired assets and assumed liabilities in business combinations, provision for credit losses, inventory reserves, deferred income taxes, the estimated useful life and recoverability of long-lived assets, contingent consideration, accounting for debt extinguishment and the royalty financing liability, and the valuation of stock-based awards and other items as appropriate. Actual results could differ from those estimates.</span>
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	900000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	100000
CY2022Q4	us-gaap	Inventory Adjustments InventoryAdjustments	2900000
CY2021Q4	us-gaap	Inventory Adjustments InventoryAdjustments	6000000.0
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	223000
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	2589000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
CY2022	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	67700000
CY2022Q4	us-gaap	Goodwill Goodwill	0
CY2021Q4	us-gaap	Goodwill Goodwill	0
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1700000
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1800000
CY2022	atnx	Impairment Of Continuing Operations ImpairmentOfContinuingOperations	100000
CY2022	atnx	Impairment Of Discontinued Operations ImpairmentOfDiscontinuedOperations	1700000
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	5718000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk, Other Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and short-term investments. The Company deposits its cash equivalents in interest-bearing money market accounts and certificates of deposit and invests in highly liquid U.S. Treasury notes, commercial paper, and corporate bonds. The Company deposits its cash with multiple financial institutions. Cash balances exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility, and research and development facility in China, and therefore is subject to foreign currency fluctuation and regulatory uncertainties.</span></p>
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-5448000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-41682000
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	7308000
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	72528000
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	95369000
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-198641000
CY2022Q4	us-gaap	Inventory Raw Materials And Purchased Parts Net Of Reserves InventoryRawMaterialsAndPurchasedPartsNetOfReserves	5703000
CY2021Q4	us-gaap	Inventory Raw Materials And Purchased Parts Net Of Reserves InventoryRawMaterialsAndPurchasedPartsNetOfReserves	2959000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	69000
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	36882000
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	20097000
CY2022Q4	us-gaap	Inventory Net InventoryNet	42654000
CY2021Q4	us-gaap	Inventory Net InventoryNet	23068000
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2685000
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2636000
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	75000
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	3714000
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	690000
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1192000
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	238000
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	147000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6277000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7912000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4453000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4721000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1824000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3191000
CY2022	us-gaap	Depreciation Depreciation	1100000
CY2021	us-gaap	Depreciation Depreciation	1400000
CY2020Q4	us-gaap	Goodwill Goodwill	38891000
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	28711000
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-77000
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	67679000
CY2022	us-gaap	Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-10000
CY2022	us-gaap	Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-10000
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	79802000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7612000
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	78000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	72112000
CY2021	us-gaap	Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-10000
CY2021	us-gaap	Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-10000
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	83577000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9941000
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1740000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	71896000
CY2022	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P6Y7D
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1800000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1803000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1476000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1410000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	822000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	627000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	434000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6572000
CY2022	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2
CY2022Q4	atnx	Fair Value Liabilities Level2 To Level1 Transfers Amount1 FairValueLiabilitiesLevel2ToLevel1TransfersAmount1	0
CY2021Q4	atnx	Fair Value Liabilities Level2 To Level1 Transfers Amount1 FairValueLiabilitiesLevel2ToLevel1TransfersAmount1	0
CY2022Q4	atnx	Fair Value Liabilities Level1 To Level2 Transfers Amount1 FairValueLiabilitiesLevel1ToLevel2TransfersAmount1	0
CY2021Q4	atnx	Fair Value Liabilities Level1 To Level2 Transfers Amount1 FairValueLiabilitiesLevel1ToLevel2TransfersAmount1	0
CY2022Q4	atnx	Fair Value Assets Level1 To Level2 Transfers Amount1 FairValueAssetsLevel1ToLevel2TransfersAmount1	0
CY2021Q4	atnx	Fair Value Assets Level1 To Level2 Transfers Amount1 FairValueAssetsLevel1ToLevel2TransfersAmount1	0
CY2022Q4	atnx	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2021Q4	atnx	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	20272000
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	106631000
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	30590000
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	24076000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2022Q4	atnx	Accrued Selling Fees Rebates And Royalties AccruedSellingFeesRebatesAndRoyalties	11290000
CY2021Q4	atnx	Accrued Selling Fees Rebates And Royalties AccruedSellingFeesRebatesAndRoyalties	6890000
CY2022Q4	atnx	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	8581000
CY2021Q4	atnx	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	3116000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5868000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1827000
CY2022Q4	atnx	Accrued Inventory Purchases Current AccruedInventoryPurchasesCurrent	3555000
CY2021Q4	atnx	Accrued Inventory Purchases Current AccruedInventoryPurchasesCurrent	4218000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2823000
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2798000
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1750000
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1800000
CY2022Q4	atnx	Accrued Operating Expenses Current AccruedOperatingExpensesCurrent	1469000
CY2021Q4	atnx	Accrued Operating Expenses Current AccruedOperatingExpensesCurrent	2647000
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	29000
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	116000
CY2021Q4	atnx	Accrued Interest AccruedInterest	266000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	35365000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23678000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10600000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-93979000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-153505000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4649000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-17453000
CY2022	atnx	Income Loss From Continuing And Discontinuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingAndDiscontinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-98628000
CY2021	atnx	Income Loss From Continuing And Discontinuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingAndDiscontinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-170958000
CY2022	atnx	Income Loss From Discontinuing Operations Before Income Taxes Domestic IncomeLossFromDiscontinuingOperationsBeforeIncomeTaxesDomestic	8922000
CY2021	atnx	Income Loss From Discontinuing Operations Before Income Taxes Domestic IncomeLossFromDiscontinuingOperationsBeforeIncomeTaxesDomestic	-30094000
CY2022	atnx	Income Loss From Discontinuing Operations Before Income Taxes Foreign IncomeLossFromDiscontinuingOperationsBeforeIncomeTaxesForeign	-13176000
CY2021	atnx	Income Loss From Discontinuing Operations Before Income Taxes Foreign IncomeLossFromDiscontinuingOperationsBeforeIncomeTaxesForeign	-11588000
CY2022	atnx	Income Loss From Discontinuing Operations Before Income Taxes IncomeLossFromDiscontinuingOperationsBeforeIncomeTaxes	-4254000
CY2021	atnx	Income Loss From Discontinuing Operations Before Income Taxes IncomeLossFromDiscontinuingOperationsBeforeIncomeTaxes	-41682000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	13000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	344000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	234000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	347000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	247000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-33522000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	8917000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-452000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-246000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-211000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	229000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-34185000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	8900000
CY2022	atnx	Valuation Allowance Deferred Tax Asset Change In Amount Continuing Operations ValuationAllowanceDeferredTaxAssetChangeInAmountContinuingOperations	-34185000
CY2021	atnx	Valuation Allowance Deferred Tax Asset Change In Amount Continuing Operations ValuationAllowanceDeferredTaxAssetChangeInAmountContinuingOperations	19751000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	347000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10604000
CY2022	atnx	Current Foreign Tax Expense Benefit Discontinuing Operations CurrentForeignTaxExpenseBenefitDiscontinuingOperations	1194000
CY2022	atnx	Current Income Tax Expense Benefit Discontinuing Operations CurrentIncomeTaxExpenseBenefitDiscontinuingOperations	1194000
CY2022	atnx	Deferred Federal Income Tax Expense Benefit Discontinuing Operations DeferredFederalIncomeTaxExpenseBenefitDiscontinuingOperations	-356000
CY2021	atnx	Deferred Federal Income Tax Expense Benefit Discontinuing Operations DeferredFederalIncomeTaxExpenseBenefitDiscontinuingOperations	-2818000
CY2022	atnx	Deferred State And Local Income Tax Expense Benefit Discontinuing Operations DeferredStateAndLocalIncomeTaxExpenseBenefitDiscontinuingOperations	34000
CY2021	atnx	Deferred State And Local Income Tax Expense Benefit Discontinuing Operations DeferredStateAndLocalIncomeTaxExpenseBenefitDiscontinuingOperations	-88000
CY2022	atnx	Deferred Foreign Income Tax Expense Benefit Discontinuing Operations DeferredForeignIncomeTaxExpenseBenefitDiscontinuingOperations	3303000
CY2021	atnx	Deferred Foreign Income Tax Expense Benefit Discontinuing Operations DeferredForeignIncomeTaxExpenseBenefitDiscontinuingOperations	29000
CY2022	atnx	Deferred Income Tax Expense Benefit Discontinuing Operations DeferredIncomeTaxExpenseBenefitDiscontinuingOperations	2981000
CY2021	atnx	Deferred Income Tax Expense Benefit Discontinuing Operations DeferredIncomeTaxExpenseBenefitDiscontinuingOperations	-2877000
CY2022	atnx	Valuation Allowance Deferred Tax Asset Change In Amount Discontinuing Operations ValuationAllowanceDeferredTaxAssetChangeInAmountDiscontinuingOperations	2981000
CY2021	atnx	Valuation Allowance Deferred Tax Asset Change In Amount Discontinuing Operations ValuationAllowanceDeferredTaxAssetChangeInAmountDiscontinuingOperations	-2877000
CY2022	atnx	Income Tax Expense Benefit Discontinuing Operations IncomeTaxExpenseBenefitDiscontinuingOperations	1194000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.004
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.004
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.347
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.116
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.007
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.051
CY2022	atnx	Effective Income Tax Rate Reconciliation Section Three Eight Two Limitation EffectiveIncomeTaxRateReconciliationSectionThreeEightTwoLimitation	0.078
CY2021	atnx	Effective Income Tax Rate Reconciliation Section Three Eight Two Limitation EffectiveIncomeTaxRateReconciliationSectionThreeEightTwoLimitation	-0.134
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.062
CY2022	atnx	Effective Income Tax Rate Reconciliation Foreign Tax Withholdings EffectiveIncomeTaxRateReconciliationForeignTaxWithholdings	-0.003
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies Foreign EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign	0.064
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.014
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.062
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	12042000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	11675000

CY2022Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

CY2022

us-gaap

Impairment Of Intangible Asset Indefinite Lived Excluding Goodwill Statement Of Income Or Comprehensive Income Extensible Enumeration

ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration

http://fasb.org/us-gaap/2022#GoodwillAndIntangibleAssetImpairment

CY2022

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2022Q4

us-gaap

Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List

FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList

http://www.athenex.com/20221231#LongTermDebtAndFinanceLeaseObligationsNonCurrent

CY2021Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

CY2021

us-gaap

Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration

ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration

http://fasb.org/us-gaap/2022#GoodwillAndIntangibleAssetImpairment

CY2021Q4

us-gaap

Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List

FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet

CY2022

dei

Entity Central Index Key

EntityCentralIndexKey

0001300699

CY2021Q4

us-gaap

Finance Lease Liability Current Statement Of Financial Position Extensible List

FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent

CY2022

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

FY

CY2022Q4

us-gaap

Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List

FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet

CY2022

dei

Entity Filer Category

EntityFilerCategory

Non-accelerated Filer

CY2022Q4

us-gaap

Finance Lease Liability Current Statement Of Financial Position Extensible List

FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent

CY2022

dei

Amendment Flag

AmendmentFlag

false

CY2022Q4

us-gaap

Short Term Investments

ShortTermInvestments

1071000

CY2021Q4

us-gaap

Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List

FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList

http://www.athenex.com/20221231#LongTermDebtAndFinanceLeaseObligationsNonCurrent

CY2022

us-gaap

Discontinued Operation Gain Loss On Disposal Statement Of Income Or Comprehensive Income Extensible Enumeration

DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration

http://fasb.org/us-gaap/2022#IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

CY2022

dei

Document Type

DocumentType

10-K

CY2022

dei

Document Annual Report

DocumentAnnualReport

true

CY2022

dei

Document Period End Date

DocumentPeriodEndDate

2022-12-31

CY2022

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2022

CY2022

dei

Document Transition Report

DocumentTransitionReport

false

CY2022

dei

Entity File Number

EntityFileNumber

001-38112

CY2022

dei

Entity Registrant Name

EntityRegistrantName

ATHENEX, INC.

CY2022

dei

Entity Incorporation State Country Code

EntityIncorporationStateCountryCode

DE

CY2022

dei

Entity Tax Identification Number

EntityTaxIdentificationNumber

43-1985966

CY2022

dei

Entity Address Address Line1

EntityAddressAddressLine1

1001 Main Street

CY2022

dei

Entity Address Address Line2

EntityAddressAddressLine2

Suite 600

CY2022

dei

Entity Address City Or Town

EntityAddressCityOrTown

Buffalo

CY2022

dei

Entity Address State Or Province

EntityAddressStateOrProvince

NY

CY2022

dei

Entity Address Postal Zip Code

EntityAddressPostalZipCode

14203

CY2022

dei

City Area Code

CityAreaCode

716

CY2022

dei

Local Phone Number

LocalPhoneNumber

427-2950

CY2022

dei

Security12b Title

Security12bTitle

Common Stock, par value $0.001 per share

CY2022

dei

Trading Symbol

TradingSymbol

ATNX

CY2022

dei

Security Exchange Name

SecurityExchangeName

NASDAQ

CY2022

dei

Entity Well Known Seasoned Issuer

EntityWellKnownSeasonedIssuer

No

CY2022

dei

Entity Voluntary Filers

EntityVoluntaryFilers

No

CY2022

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2022

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

CY2022

dei

Entity Small Business

EntitySmallBusiness

true

CY2022

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

CY2022

dei

Icfr Auditor Attestation Flag

IcfrAuditorAttestationFlag

false

CY2022

dei

Entity Shell Company

EntityShellCompany

false

CY2022Q2

dei

Entity Public Float

EntityPublicFloat

32500000

CY2023Q1

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

8663209

CY2022

dei

Auditor Firm

AuditorFirmId

34

CY2022

dei

Auditor Name

AuditorName

Deloitte & Touche LLP

CY2022

dei

Auditor Location

AuditorLocation

Williamsville, New York

CY2022Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

30437000

CY2021Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

35202000

CY2022Q4

us-gaap

Restricted Cash Current

RestrictedCashCurrent

5183000

CY2021Q4

us-gaap

Restricted Cash Current

RestrictedCashCurrent

16500000

CY2021Q4

us-gaap

Short Term Investments

ShortTermInvestments

10207000

CY2022Q4

atnx

Chargebacks And Other Deductions Current

ChargebacksAndOtherDeductionsCurrent

29470000

CY2021Q4

atnx

Chargebacks And Other Deductions Current

ChargebacksAndOtherDeductionsCurrent

22869000

CY2022Q4

us-gaap

Allowance For Doubtful Accounts Receivable Current

AllowanceForDoubtfulAccountsReceivableCurrent

9676000

CY2021Q4

us-gaap

Allowance For Doubtful Accounts Receivable Current

AllowanceForDoubtfulAccountsReceivableCurrent

9069000

CY2022Q4

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

27865000

CY2021Q4

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

22778000

CY2022Q4

us-gaap

Inventory Net

InventoryNet

42654000

CY2021Q4

us-gaap

Inventory Net

InventoryNet

23068000

CY2022Q4

us-gaap

Prepaid Expense And Other Assets Current

PrepaidExpenseAndOtherAssetsCurrent

10578000

CY2021Q4

us-gaap

Prepaid Expense And Other Assets Current

PrepaidExpenseAndOtherAssetsCurrent

5337000

CY2022Q4

us-gaap

Assets Of Disposal Group Including Discontinued Operation Current

AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

7141000

CY2021Q4

us-gaap

Assets Of Disposal Group Including Discontinued Operation Current

AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

20303000

CY2022Q4

us-gaap

Assets Current

AssetsCurrent

124929000

CY2021Q4

us-gaap

Assets Current

AssetsCurrent

133395000

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

1824000

CY2021Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3191000

CY2022Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

72112000

CY2021Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

71896000

CY2022Q4

us-gaap

Operating Lease Right Of Use Asset

OperatingLeaseRightOfUseAsset

4219000

CY2021Q4

us-gaap

Operating Lease Right Of Use Asset

OperatingLeaseRightOfUseAsset

5670000

CY2022Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

804000

CY2021Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1071000

CY2022Q4

us-gaap

Disposal Group Including Discontinued Operation Assets Noncurrent

DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent

167000

CY2021Q4

us-gaap

Disposal Group Including Discontinued Operation Assets Noncurrent

DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent

52225000

CY2022Q4

us-gaap

Assets

204055000

CY2021Q4

us-gaap

Assets

267448000

CY2022Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

33682000

CY2021Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

12485000

CY2022Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

35365000

CY2021Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

23678000

CY2022Q4

us-gaap

Operating Lease Liability Current

OperatingLeaseLiabilityCurrent

2087000

CY2021Q4

us-gaap

Operating Lease Liability Current

OperatingLeaseLiabilityCurrent

2478000

CY2022Q4

us-gaap

Long Term Debt And Capital Lease Obligations Current

LongTermDebtAndCapitalLeaseObligationsCurrent

37127000

CY2021Q4

us-gaap

Long Term Debt And Capital Lease Obligations Current

LongTermDebtAndCapitalLeaseObligationsCurrent

46076000

CY2022Q4

us-gaap

Business Combination Contingent Consideration Liability Current

BusinessCombinationContingentConsiderationLiabilityCurrent

900000

CY2022Q4

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Current

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

5718000

CY2021Q4

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Current

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

11331000

CY2022Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

114879000

CY2021Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

96048000

CY2022Q4

us-gaap

Operating Lease Liability Noncurrent

OperatingLeaseLiabilityNoncurrent

3051000

CY2021Q4

us-gaap

Operating Lease Liability Noncurrent

OperatingLeaseLiabilityNoncurrent

4494000

CY2022Q4

atnx

Long Term Debt And Finance Lease Obligations Non Current

LongTermDebtAndFinanceLeaseObligationsNonCurrent

93000

CY2021Q4

atnx

Long Term Debt And Finance Lease Obligations Non Current

LongTermDebtAndFinanceLeaseObligationsNonCurrent

95607000

CY2022Q4

atnx

Royalty Financing Liability Noncurrent

RoyaltyFinancingLiabilityNoncurrent

86745000

CY2022Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

1751000

CY2021Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

1751000

CY2022Q4

us-gaap

Business Combination Contingent Consideration Liability Noncurrent

BusinessCombinationContingentConsiderationLiabilityNoncurrent

18986000

CY2021Q4

us-gaap

Business Combination Contingent Consideration Liability Noncurrent

BusinessCombinationContingentConsiderationLiabilityNoncurrent

24076000

CY2022Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

2731000

CY2021Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

3046000

CY2021Q4

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Noncurrent

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent

7974000

CY2022Q4

us-gaap

Liabilities

228236000

CY2021Q4

us-gaap

Liabilities

232996000

CY2022Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2021Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2022Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

25000000

CY2021Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

12500000

CY2022Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

8711696

CY2021Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

5590149

CY2022Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

8626769

CY2021Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

5506503

CY2022Q4

us-gaap

Common Stock Value

CommonStockValue

9000

CY2021Q4

us-gaap

Common Stock Value

CommonStockValue

6000

CY2022Q4

us-gaap

Additional Paid In Capital Common Stock

AdditionalPaidInCapitalCommonStock

1017194000

CY2021Q4

us-gaap

Additional Paid In Capital Common Stock

AdditionalPaidInCapitalCommonStock

972509000

CY2022Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

887000

CY2021Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-487000

CY2022Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-1016839000

CY2021Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-913412000

CY2022Q4

us-gaap

Treasury Stock Shares

TreasuryStockShares

84928

CY2021Q4

us-gaap

Treasury Stock Shares

TreasuryStockShares

83646

CY2022Q4

us-gaap

Treasury Stock Value

TreasuryStockValue

7757000

CY2021Q4

us-gaap

Treasury Stock Value

TreasuryStockValue

7485000

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

-6506000

CY2021Q4

us-gaap

Stockholders Equity

StockholdersEquity

51131000

CY2022Q4

us-gaap

Minority Interest

MinorityInterest

-17675000

CY2021Q4

us-gaap

Minority Interest

MinorityInterest

-16679000

CY2022Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

-24181000

CY2021Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

34452000

CY2022Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

204055000

CY2021Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

267448000

CY2022

us-gaap

Revenue From Contract With Customer Excluding Assessed Tax

RevenueFromContractWithCustomerExcludingAssessedTax

102821000

CY2021

us-gaap

Revenue From Contract With Customer Excluding Assessed Tax

RevenueFromContractWithCustomerExcludingAssessedTax

95369000

CY2022

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

76118000

CY2021

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

62892000

CY2022

us-gaap

Gross Profit

GrossProfit

26703000

CY2021

us-gaap

Gross Profit

GrossProfit

32477000

CY2022

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

51758000

CY2021

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

77668000

CY2022

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

44880000

CY2021

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

64230000

CY2022

us-gaap

Goodwill And Intangible Asset Impairment

GoodwillAndIntangibleAssetImpairment

79000

CY2021

us-gaap

Goodwill And Intangible Asset Impairment

GoodwillAndIntangibleAssetImpairment

41011000

CY2022

us-gaap

Operating Expenses

OperatingExpenses

96717000

CY2021

us-gaap

Operating Expenses

OperatingExpenses

182909000

CY2022

us-gaap

Operating Income Loss

OperatingIncomeLoss

-70014000

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

-150432000

CY2022

us-gaap

Investment Income Interest

InvestmentIncomeInterest

363000

CY2021

us-gaap

Investment Income Interest

InvestmentIncomeInterest

128000

CY2022

us-gaap

Interest Expense

InterestExpense

25843000

CY2021

us-gaap

Interest Expense

InterestExpense

20654000

CY2022

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-3134000

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-98628000

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-170958000

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

347000

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

-10604000

CY2022

us-gaap

Income Loss From Continuing Operations

IncomeLossFromContinuingOperations

-98975000

CY2021

us-gaap

Income Loss From Continuing Operations

IncomeLossFromContinuingOperations

-160354000

CY2022

us-gaap

Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity

IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

-5448000

CY2021

us-gaap

Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity

IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

-41682000

CY2022

us-gaap

Profit Loss

ProfitLoss

-104423000

CY2021

us-gaap

Profit Loss

ProfitLoss

-202036000

CY2022

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

-996000

CY2021

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

-2268000

CY2022

us-gaap

Net Income Loss

NetIncomeLoss

-103427000

CY2021

us-gaap

Net Income Loss

NetIncomeLoss

-199768000

CY2022

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

465000

CY2021

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

506000

CY2022

us-gaap

Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

909000

CY2021

us-gaap

Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

141000

CY2022

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-102053000

CY2021

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-199121000

CY2022

us-gaap

Income Loss From Continuing Operations Per Basic Share

IncomeLossFromContinuingOperationsPerBasicShare

-14.98

CY2022

us-gaap

Income Loss From Continuing Operations Per Diluted Share

IncomeLossFromContinuingOperationsPerDilutedShare

-14.98

CY2021

us-gaap

Income Loss From Continuing Operations Per Basic Share

IncomeLossFromContinuingOperationsPerBasicShare

-30.42

CY2021

us-gaap

Income Loss From Continuing Operations Per Diluted Share

IncomeLossFromContinuingOperationsPerDilutedShare

-30.42

CY2022

us-gaap

Income Loss From Discontinued Operations Net Of Tax Per Basic Share

IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare

-0.83

CY2022

us-gaap

Income Loss From Discontinued Operations Net Of Tax Per Diluted Share

IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare

-0.83

CY2021

us-gaap

Income Loss From Discontinued Operations Net Of Tax Per Basic Share

IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare

-8.02

CY2021

us-gaap

Income Loss From Discontinued Operations Net Of Tax Per Diluted Share

IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare

-8.02

CY2022

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-15.81

CY2022

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-15.81

CY2021

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-38.44

CY2021

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-38.44

CY2022

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

6541068

CY2022

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

6541068

CY2021

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

5196923

CY2021

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

5196923

CY2020Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

165348000

CY2021

atnx

Stock Issuance Costs

StockIssuanceCosts

35000

CY2021

atnx

Sale Of Common Stock Through Atm And Employee Stock Purchase Plan Value

SaleOfCommonStockThroughAtmAndEmployeeStockPurchasePlanValue

1342000

CY2021

us-gaap

Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition

AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition

8591000

CY2021

us-gaap

Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition

AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition

616000

CY2021

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

1579000

CY2021

us-gaap

Treasury Stock Value Acquired Cost Method

TreasuryStockValueAcquiredCostMethod

79000

CY2021

us-gaap

Noncontrolling Interest Increase From Sale Of Parent Equity Interest

NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest

16000

CY2021

us-gaap

Profit Loss

ProfitLoss

-202036000

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

647000

CY2021Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

34452000

CY2022

atnx

Stock Issuance Costs

StockIssuanceCosts

291000

CY2022

atnx

Sale Of Common Stock Through Atm Value

SaleOfCommonStockThroughAtmValue

9395000

CY2022

atnx

Sale Of Common Stock Through Espp Value

SaleOfCommonStockThroughEsppValue

545000

CY2022

us-gaap

Adjustments To Additional Paid In Capital Warrant Issued

AdjustmentsToAdditionalPaidInCapitalWarrantIssued

8306000

CY2022

atnx

Sale Of Pre Funded Warrants

SaleOfPreFundedWarrants

2343000

CY2022

us-gaap

Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition

AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition

5576000

CY2022

us-gaap

Stock Issued During Period Value Restricted Stock Award Gross

StockIssuedDuringPeriodValueRestrictedStockAwardGross

750000

CY2022

us-gaap

Treasury Stock Value Acquired Cost Method

TreasuryStockValueAcquiredCostMethod

272000

CY2022

us-gaap

Profit Loss

ProfitLoss

-104423000

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

1374000

CY2022Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

-24181000

CY2022

us-gaap

Income Loss From Continuing Operations

IncomeLossFromContinuingOperations

-98975000

CY2021

us-gaap

Income Loss From Continuing Operations

IncomeLossFromContinuingOperations

-160354000

CY2022

us-gaap

Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity

IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

-5448000

CY2021

us-gaap

Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity

IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

-41682000

CY2022

atnx

Depreciation And Amortization Continuing Operations

DepreciationAndAmortizationContinuingOperations

2322000

CY2021

atnx

Depreciation And Amortization Continuing Operations

DepreciationAndAmortizationContinuingOperations

3138000

CY2022

us-gaap

Share Based Compensation

ShareBasedCompensation

6326000

CY2021

us-gaap

Share Based Compensation

ShareBasedCompensation

9207000

CY2022

us-gaap

Goodwill And Intangible Asset Impairment

GoodwillAndIntangibleAssetImpairment

79000

CY2021

us-gaap

Goodwill And Intangible Asset Impairment

GoodwillAndIntangibleAssetImpairment

41011000

CY2022

us-gaap

Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1

BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

-4190000

CY2021

us-gaap

Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1

BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

4237000

CY2022

us-gaap

Provision For Doubtful Accounts

ProvisionForDoubtfulAccounts

134000

CY2021

us-gaap

Provision For Doubtful Accounts

ProvisionForDoubtfulAccounts

-456000

CY2022

us-gaap

Amortization Of Debt Discount Premium

AmortizationOfDebtDiscountPremium

4362000

CY2021

us-gaap

Amortization Of Debt Discount Premium

AmortizationOfDebtDiscountPremium

2939000

CY2022

atnx

Change In Fair Value Of Royalty Financing Liability

ChangeInFairValueOfRoyaltyFinancingLiability

10240000

CY2022

us-gaap

Gain Loss On Disposition Of Assets1

GainLossOnDispositionOfAssets1

-442000

CY2021

us-gaap

Gain Loss On Disposition Of Assets1

GainLossOnDispositionOfAssets1

331000

CY2022

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-3134000

CY2021

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-648000

CY2021

us-gaap

Deferred Income Taxes And Tax Credits

DeferredIncomeTaxesAndTaxCredits

-10848000

CY2022

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

5221000

CY2021

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

2752000

CY2022

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

-656000

CY2021

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

-3272000

CY2022

us-gaap

Increase Decrease In Inventories

IncreaseDecreaseInInventories

19586000

CY2021

us-gaap

Increase Decrease In Inventories

IncreaseDecreaseInInventories

122000

CY2022

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

35929000

CY2021

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

-19385000

CY2022

us-gaap

Net Cash Provided By Used In Operating Activities Continuing Operations

NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

-64348000

CY2021

us-gaap

Net Cash Provided By Used In Operating Activities Continuing Operations

NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

-129796000

CY2022

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

417000

CY2021

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

474000

CY2022

atnx

Payments For Licenses

PaymentsForLicenses

1643000

CY2021

atnx

Payments For Licenses

PaymentsForLicenses

2137000

CY2021

us-gaap

Cash Acquired From Acquisition

CashAcquiredFromAcquisition

1425000

CY2021

us-gaap

Proceeds From Divestiture Of Businesses Net Of Cash Divested

ProceedsFromDivestitureOfBusinessesNetOfCashDivested

101000

CY2022

us-gaap

Payments To Acquire Short Term Investments

PaymentsToAcquireShortTermInvestments

9087000

CY2021

us-gaap

Payments To Acquire Short Term Investments

PaymentsToAcquireShortTermInvestments

68672000

CY2022

us-gaap

Proceeds From Sale Of Short Term Investments

ProceedsFromSaleOfShortTermInvestments

18683000

CY2021

us-gaap

Proceeds From Sale Of Short Term Investments

ProceedsFromSaleOfShortTermInvestments

197608000

CY2022

us-gaap

Net Cash Provided By Used In Investing Activities Continuing Operations

NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

7536000

CY2021

us-gaap

Net Cash Provided By Used In Investing Activities Continuing Operations

NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

127851000

CY2022

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

29177000

CY2021

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

1343000

CY2022

atnx

Proceeds From Issuance Of Royalty Financing Liability

ProceedsFromIssuanceOfRoyaltyFinancingLiability

81500000

CY2022

atnx

Proceeds From Issuance Of Warrants And Pre Funded Warrants

ProceedsFromIssuanceOfWarrantsAndPreFundedWarrants

11050000

CY2022

us-gaap

Payments Of Stock Issuance Costs

PaymentsOfStockIssuanceCosts

1464000

CY2022

atnx

Payments For Issuance Of Warrants And Pre Funded Warrants

PaymentsForIssuanceOfWarrantsAndPreFundedWarrants

684000

CY2022

atnx

Payments For Issuance Of Royalty Financing Liability

PaymentsForIssuanceOfRoyaltyFinancingLiability

4982000

CY2022

atnx

Costs Incurred Related To The Prepayment Of Debt

CostsIncurredRelatedToThePrepaymentOfDebt

6515000

CY2021

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

1579000

CY2022

atnx

Payments For Repurchase Of Treasury Stock

PaymentsForRepurchaseOfTreasuryStock

272000

CY2021

atnx

Payments For Repurchase Of Treasury Stock

PaymentsForRepurchaseOfTreasuryStock

79000

CY2022

atnx

Repayment Of Finance Lease Obligations And Long Term Debt And Royalty Financing Liability

RepaymentOfFinanceLeaseObligationsAndLongTermDebtAndRoyaltyFinancingLiability

105439000

CY2021

atnx

Repayment Of Finance Lease Obligations And Long Term Debt And Royalty Financing Liability

RepaymentOfFinanceLeaseObligationsAndLongTermDebtAndRoyaltyFinancingLiability

106000

CY2022

us-gaap

Net Cash Provided By Used In Financing Activities Continuing Operations

NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

2371000

CY2021

us-gaap

Net Cash Provided By Used In Financing Activities Continuing Operations

NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

2737000

CY2022

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-54441000

CY2021

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

792000

CY2022

us-gaap

Cash Provided By Used In Operating Activities Discontinued Operations

CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations

-10666000

CY2021

us-gaap

Cash Provided By Used In Operating Activities Discontinued Operations

CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations

-12585000

CY2022

us-gaap

Cash Provided By Used In Investing Activities Discontinued Operations

CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations

50366000

CY2021

us-gaap

Cash Provided By Used In Investing Activities Discontinued Operations

CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations

-22866000

CY2022

us-gaap

Cash Provided By Used In Financing Activities Discontinued Operations

CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations

-807000

CY2021

us-gaap

Cash Provided By Used In Financing Activities Discontinued Operations

CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations

-274000

CY2022

us-gaap

Net Cash Provided By Used In Discontinued Operations

NetCashProvidedByUsedInDiscontinuedOperations

38893000

CY2021

us-gaap

Net Cash Provided By Used In Discontinued Operations

NetCashProvidedByUsedInDiscontinuedOperations

-35725000

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

51702000

CY2020Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

86087000

CY2022

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

-534000

CY2021

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

548000

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

35620000

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

51702000

CY2022

us-gaap

Interest Paid Net

InterestPaidNet

11088000

CY2021

us-gaap

Interest Paid Net

InterestPaidNet

20336000

CY2022

us-gaap

Income Taxes Paid

IncomeTaxesPaid

586000

CY2021

us-gaap

Income Taxes Paid

IncomeTaxesPaid

108000

CY2022

atnx

Accrued Purchases Of Property And Equipment From Continuing Operations

AccruedPurchasesOfPropertyAndEquipmentFromContinuingOperations

21000

CY2021

atnx

Accrued Purchases Of Property And Equipment From Continuing Operations

AccruedPurchasesOfPropertyAndEquipmentFromContinuingOperations

246000

CY2021

atnx

Accrued Purchases Of Property And Equipment From Discontinued Operations

AccruedPurchasesOfPropertyAndEquipmentFromDiscontinuedOperations

1679000

CY2022

atnx

Modification Of Warrants

ModificationOfWarrants

283000

CY2022

atnx

Accrued Purchases Of Licenses

AccruedPurchasesOfLicenses

1138000

CY2021

atnx

Accrued Purchases Of Licenses

AccruedPurchasesOfLicenses

1250000

CY2022

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

146000

CY2021

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

203000

CY2022

atnx

Right Of Use Assets Derecognized From Modification Of Operating Lease Obligations

RightOfUseAssetsDerecognizedFromModificationOfOperatingLeaseObligations

128000

CY2021

atnx

Right Of Use Assets Derecognized From Modification Of Operating Lease Obligations

RightOfUseAssetsDerecognizedFromModificationOfOperatingLeaseObligations

114000

CY2021

us-gaap

Business Combination Consideration Transferred Equity Interests Issued And Issuable

BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable

52786000

CY2022

us-gaap

Nature Of Operations

NatureOfOperations

<div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.<div style="display:inline;">COMPANY AND NATURE OF BUSINESS </div></div>Description of Business Athenex, Inc. (the “Company” or “Athenex”), originally under the name Kinex Pharmaceuticals LLC (“Kinex”), formed in November 2003, commenced operations on February 5, 2004, and operated as a limited liability company until it was incorporated in the State of Delaware under the name Kinex Pharmaceuticals, Inc. on December 31, 2012. The Company changed its name to Athenex, Inc. on August 26, 2015. Athenex is a biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by creating more effective, safer, and accessible treatments. The Company has assembled a strong and experienced leadership team and has established operations across the pharmaceutical value chain to execute our goal of becoming a leader in bringing innovative cancer treatments to the market and improving health outcomes.The Company is organized around <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">two operating segments: (1) its Oncology Innovation Platform, dedicated to the research and development of our proprietary drugs; and (2) its Commercial Platform, focused on the sales and marketing of our specialty drugs and the market development of our proprietary drugs. The Company’s current clinical pipeline in the Oncology Innovation Platform is derived mainly from the following core technologies: (a) Cell Therapy, based on natural killer T ("NKT") cells, and (b) Orascovery, based on a P-glycoprotein pump inhibitor. The Company previously had a third operating segment, the Global Supply Chain Platform, focused on the current Good Manufacturing Practices ("cGMP") manufacturing and supply of active pharmaceutical ingredients and 503B sterile compounded pharmaceutical products. The components within this operating segment were discontinued during 2022 and are reported as discontinued operations. Refer to Note 3 – Discontinued Operations for additional information.The Company is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities. The Company also conducts commercial sales of specialty products through its wholly owned subsidiary, Athenex Pharmaceutical Division (“APD”).Going ConcernThese consolidated financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.The Company has incurred operating losses since its inception and, as a result, as of December 31, 2022 and 2021 had an accumulated deficit of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,016.8 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">913.4 million, respectively. As of December 31, 2022, the Company had cash and cash equivalents of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">30.4 million, restricted cash of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.2 million, and short-term investments of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.1 million. The Company projects insufficient liquidity to fund its operations through the next twelve months beyond the date of the issuance of these consolidated financial statements. This condition raises substantial doubt about the Company’s ability to continue as a going concern. <div style="font-size:10.0pt;font-family:"Times New Roman", serif;">The Company is in compliance with the minimum liquidity and minimum revenue financial covenants in the Senior Credit Agreement as of December 31, 2022. However, the Company received notices of certain alleged defaults and reservations of rights related to the Senior Credit Agreement, as described in Note 12 - Debt and Lease Obligations, and is forecasting noncompliance with the minimum liquidity covenant and minimum revenue covenant included within the Senior Credit Agreement during the twelve month period subsequent to the date of this filing. Pursuant to ASC 205-40-50, the Company’s forecast and analysis herein does not reflect management’s plans that are outside of the Company’s control as described below. Violation of any covenant under the Senior Credit Agreement provides the lenders with the option to accelerate the maturity of the amounts due under the Senior Credit Agreement, which was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">44.7 million as of December 31, 2022. Should the lenders accelerate the maturity of the amounts due under the Senior Credit Agreement, the Company would not have sufficient cash on hand or available liquidity to repay the outstanding debt. These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern.</div>In response to these conditions, management’s plans include seeking additional funding through asset monetization, seeking funding through alternative means, and raising capital. There can be no assurances, however, that the Company will be able to monetize assets or obtain additional funding on favorable terms, or at all. Because management’s plans have not yet been finalized and are not within the Company’s control, such plans cannot be considered probable of being achieved. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Other Significant Risks and UncertaintiesIn February 2021, the Company received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s New Drug Application (“NDA”) for oral paclitaxel and encequidar (“Oral Paclitaxel”) for the treatment of metastatic breast cancer (“mBC”), indicating that the application is not ready for approval in its present form. In the CRL, the FDA indicated its concern of safety risk to patients in terms of an increase in neutropenia-related sequelae on the Oral Paclitaxel arm compared with the IV paclitaxel arm in the Phase III study. The FDA also expressed concerns regarding the uncertainty over the results of the primary endpoint of objective response rate at week 19 conducted by blinded independent central review. During the second quarter of 2021, the Company held a Type A meeting with the FDA, where it provided additional analyses, including overall survival data on patient subgroups, to provide a more comprehensive summary of the risk/benefit assessment. In October 2021, after careful consideration of the FDA’s feedback, the Company determined to redeploy its resources to focus on the cell therapy platform and ongoing studies of Oral Paclitaxel.The Company is subject to a number of risks, including, but not limited to, the lack of available capital; the possible delisting of our common stock from Nasdaq; possible failure of preclinical testing or clinical trials; inability to obtain regulatory approval of product candidates; competitors developing new technological innovations; potential interruptions in the manufacturing and commercial supply operations; unsuccessful commercialization strategy and launch plans for its proprietary drug candidates; risks inherent in litigation, including purported class actions; market acceptance of the Company’s products; and protection of proprietary technology. If the Company or its partners do not successfully commercialize any of the Company’s product candidates, it will be unable to generate sufficient revenue and might not, if ever, achieve profitability and positive cash flow. Recent Financing ActivityPublic Offering of Common Stock and WarrantsIn August 2022, the Company completed an underwritten public offering in which it sold <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,766,667 shares of common stock, common warrants to purchase up to <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,000,000 shares of common stock at a price of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">20.00 per share, and pre-funded warrants to purchase up to <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">233,334 shares of common stock at a price of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.02 per share. The shares of common stock, together with the common warrants, were sold at $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">15.00 per share and accompanying common warrant, and the pre-funded warrants, together with the common warrants, were sold at $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14.98 per pre-funded warrant and accompanying common warrant. The common and pre-funded warrants were exercisable immediately and will expire five years from the date of issuance. The Company received net proceeds of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">28.1 million, after deducting discounts, commissions, and offering expenses.At-the-market offeringOn August 20, 2021, the Company entered into a sales agreement (the “Sales Agreement”) with SVB Leerink LLC, in connection with the offer and sale of up to $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">100,000,000 of shares of the Company’s common stock, par value $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.001 per share (“ATM Shares”). The ATM Shares to be offered and sold under the Sales Agreement will be issued and sold pursuant to a registration statement on Form S-3 (File No. 333-258185) that became effective on August 12, 2021. During the year ended December 31, 2022, the Company sold <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,263,251 shares of its common stock for an average price of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.40 per share under the Sales Agreement. During the year ended December 31, 2021, the Company sold <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">38,142 shares of its common stock for an average price of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">29.80 per share under the Sales Agreement. Sale of U.S. and European tirbanibulin royalty and milestone interestsOn June 21, 2022, the Company and ATNX SPV, LLC, its newly-formed subsidiary (the "SPV"), entered into a Revenue Interest Purchase Agreement (the “RIPA”) with affiliates of Sagard Healthcare Partners (“Sagard”) and funds managed by Oaktree (together with Sagard, the “Purchasers”), for the sale of revenues from U.S. and European royalty and milestone interests in Klisyri® (tirbanibulin) for an aggregate purchase price of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">85.0 million (“Purchase Price”). On June 29, 2022, the Purchasers paid the Company the Purchase Price. Of the total Purchase Price, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.0 million was placed into escrow to be paid to the Company upon the satisfaction of certain manufacture and supply milestones for Klisyri prior to December 31, 2025, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.0 million was used to pay for transaction expenses, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">56.6 million was used to pay down principal, interest, and fees on the Company's Senior Credit Agreement with Oaktree, and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.5 million was deposited and held in a segregated account of the Company (the “Segregated Funds”). The Segregated Funds were released to the Company upon the underwritten public offering in August 2022 and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.5 million of the amount placed in escrow was released to the Company upon completion of an escrow release trigger milestone in September 2022. The $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.5 million of Segregated Funds and the remaining proceeds of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.9 million were available for the Company's operations. Refer to Note 12 - Debt and Lease Obligations for additional information.In connection with this transaction, the Company formed the SPV and contributed its interest in the License and Development Agreement with Almirall S.A. relating to Klisyri (the “License Agreement”) and certain related assets to the SPV. Oaktree and Sagard each own a <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10% equity interest in the SPV. Pursuant to the RIPA, the SPV will sell its right to the cash received in respect of certain royalties and certain milestone interests under the License Agreement to the Purchasers. The SPV will retain the right to receive <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50% of certain of the milestone interests under the License Agreement, equal to $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">155.0 million in the aggregate if those milestones are achieved, and <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50% of the royalties paid under the License Agreement for sales of Klisyri once net sales of Klisyri exceed a certain dollar amount. Under its operating agreement, the SPV will be governed by a five-member board of directors to which the Company will appoint three directors, Oaktree will appoint one director, and Sagard will appoint one director.Senior Secured Loan Agreement and Detachable WarrantsOn June 19, 2020, the Company entered into a senior secured loan agreement and related security agreements (the “Senior Credit Agreement”) with Oaktree to borrow up to $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">225.0 million in <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">five tranches with a maturity date of June 19, 2026, bearing interest at a fixed annual rate of <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11.0%. The first tranche of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">100.0 million was drawn by the Company prior to June 30, 2020, with the proceeds used in part to repay in full the outstanding loan and fees under the credit agreement with Perceptive Advisors LLC and its affiliates. The second and third tranches of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">25.0 million each were drawn by the Company prior to December 31, 2020. The additional debt tranches amounting to an aggregate of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75.0 million were subject to the approval Oral Paclitaxel in the treatment of mBC, and therefore, became unavailable to the Company when it decided to no longer pursue regulatory approval in the U.S. The Company was required to make quarterly interest-only payments until June 19, 2022, after which the Company is required to make quarterly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity. The loan agreement contains specified financial maintenance covenants. The Company was in compliance with such covenants as of December 31, 2022.In connection with the Senior Credit Agreement, the Company granted warrants to Oaktree to purchase an aggregate of up to <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">45,420 shares of the Company’s common stock at an initial purchase price of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">252.60 per share. This transaction was accounted for as a detachable warrant at its fair value, using the relative fair value method, which is based on a number of unobservable inputs, and is recorded as an increase to additional paid-in-capital on the consolidated statement of stockholders’ equity. The fair value of the warrants was reflected as a discount to the term loan and amortized over the life of the term loan.On January 19, 2022, the Company entered into an amendment to the Senior Credit Agreement with Oaktree (the “Third Amendment”). The Third Amendment also amended the warrants held by Oaktree and Sagard that were issued on June 19, 2020 and August 4, 2020. The Third Amendment became effective on February 14, 2022, upon the closing of the Company’s sale of its leasehold interest in the manufacturing facility in Dunkirk, New York and certain other related assets (the “Dunkirk Transaction,” see Note 3 - Discontinued Operations). The Third Amendment required the Company to make a mandatory prepayment of principal to Oaktree equal to <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">62.5% of the cash proceeds of the Dunkirk Transaction. The Company was also required to pay (i) accrued and unpaid interest and (ii) a <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.0% fee, allocated as a <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.0% Exit Fee and a <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.0% Prepayment Fee (each as defined in the Senior Credit Agreement), on the principal amount being repaid. The Company was required to pay Oaktree an amendment fee of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.3 million and certain related expenses upon the closing of the Dunkirk Transaction. The Third Amendment required the Company to make an additional mandatory prepayment of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">12.5 million in principal plus the costs and fees described above by June 14, 2022, within 120 days of the closing of the Dunkirk Transaction. Consistent with the Company’s decision to not pursue regulatory approval for Oral Paclitaxel monotherapy for the treatment of mBC in the United States, the Third Amendment reduced to zero the amount of the last <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">two tranches of borrowing that had been available under the Senior Credit Agreement upon the achievement of commercial milestones. The warrants were amended to change the exercise price to be paid per share upon exercise of the warrants. The original exercise price of the warrants was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">252.60 per share; <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50% of the shares underlying the warrants were repriced to $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">22.00 per share under the Third Amendment. The Dunkirk Transaction closed on February 14, 2022. The Company received proceeds of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">40.0 million and used these proceeds to repay $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">27.4 million, inclusive of principal, fees, and accrued interest, of the Senior Credit Agreement with Oaktree according to the terms of the Third Amendment. During June 2022, the Company made the additional prepayment under the Third Amendment in the aggregate amount of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13.7 million, inclusive of principal, fees, and accrued interest, as provided in the Fourth Amendment, described below.In June 2022, the Company entered into additional amendments to the Senior Credit Agreement with Oaktree (the "Fourth Amendment" and the "Fifth Amendment" or the "Amendments"), in connection with the execution of the RIPA with Sagard and Oaktree. Under the Fourth Amendment, Oaktree permitted the Company to pay $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.5 million in principal amount due pursuant to the Third Amendment on the closing date of the RIPA. Under the Fifth Amendment, the Company agreed to make an additional prepayment of principal to Oaktree of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.0 million on or before July 1, 2022. The Company was also required to pay (i) accrued and unpaid interest and (ii) a <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.0% fee, allocated as a <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.0% Exit Fee and a <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.0% Prepayment Fee (each as defined in the Senior Credit Agreement), on the principal amount being repaid pursuant to the Amendments. The Fourth Amendment also amended the warrants held by Oaktree and Sagard that were issued on June 19, 2020 and August 4, 2020, as previously amended on January 19, 2022. The warrants were amended to change the exercise price to be paid per share upon exercise of the warrants. The original exercise price of the warrants was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">252.60 per share. The Third Amendment had reduced the exercise price of <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50% of the shares underlying the Warrants to $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">22.00 per share, with the remaining <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50% exercisable at $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">252.60 per share. The Fourth Amendment reduced the exercise price of all of the warrants to $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.00 per share. In August 2022, the Company entered into the Sixth Amendment to the Senior Credit Agreement with Oaktree (the "Sixth Amendment"). The Sixth Amendment released the $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.5 million of Segregated Funds to the Company and required the Company to prepay an additional $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6.9 million of the Senior Credit Agreement. The Company was also required to pay (i) accrued and unpaid interest and (ii) a <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.0% fee, allocated as a <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.0% Exit Fee and a <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.0% Prepayment Fee (each as defined in the Senior Credit Agreement), on the principal amount being repaid. In early March 2023, the Company received notices of certain alleged defaults and reservations of rights from Oaktree. The alleged defaults relate to (i) the Company exceeding the $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.0 million threshold for incurring additional indebtedness by having accounts payable owed to counterparties overdue by more than 90 days, (ii) the Company’s obligation to provide notice to Oaktree related to the foregoing, and (iii) the Company’s obligation to provide notice to Oaktree regarding the recent reverse stock split. Upon the occurrence of an Event of Default, Oaktree has the right to accelerate all amounts outstanding under the Senior Credit Agreement, in addition to other remedies available to it as a secured creditor of ours. If Oaktree accelerates the maturity of the indebtedness under the Senior Credit Agreement, the Company does not have sufficient capital available to pay the amounts due on a timely basis, if at all, and there is no guarantee that the Company would be able to repay, refinance or restructure the payments due under the Senior Credit Agreement. The Company responded to Oaktree, which included grounds upon which the Company disputes each of the alleged defaults. The Company has not reached a mutual agreement with Oaktree on this matter, and given the Company is in receipt of the notices of default and reservation of rights, which could result in payment to Oaktree on demand, the amounts due and outstanding to Oaktree are presented as a current obligation of the Company.As of December 31, 2022 and 2021, the Company's outstanding principal on the Senior Credit Agreement with Oaktree amounted to $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">44.7 million, and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">150.0 million, respectively. Refer to Note 12 - Debt and Lease Obligations for additional information.Reverse Stock SplitOn February 15, 2023, the Company effected a 20:1 reverse stock split of its common stock in order to regain compliance with Nasdaq's continued listing requirements. All share and per share amounts, and exercise prices of stock options, warrants, and pre-funded warrants, if applicable, in the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split. Refer to Note 21 - Subsequent Events for additional information.

CY2022

us-gaap

Number Of Operating Segments

NumberOfOperatingSegments

2

CY2022Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-1016800000

CY2021Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-913400000

CY2022Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

30400000

CY2022Q4

us-gaap

Restricted Cash

RestrictedCash

5200000

CY2022Q4

us-gaap

Short Term Investments

ShortTermInvestments

1100000

CY2022

us-gaap

Substantial Doubt About Going Concern Conditions Or Events

SubstantialDoubtAboutGoingConcernConditionsOrEvents

The Company projects insufficient liquidity to fund its operations through the next twelve months beyond the date of the issuance of these consolidated financial statements. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company is in compliance with the minimum liquidity and minimum revenue financial covenants in the Senior Credit Agreement as of December 31, 2022. However, the Company received notices of certain alleged defaults and reservations of rights related to the Senior Credit Agreement, as described in Note 12 - Debt and Lease Obligations, and is forecasting noncompliance with the minimum liquidity covenant and minimum revenue covenant included within the Senior Credit Agreement during the twelve month period subsequent to the date of this filing. Pursuant to ASC 205-40-50, the Company’s forecast and analysis herein does not reflect management’s plans that are outside of the Company’s control as described below. Violation of any covenant under the Senior Credit Agreement provides the lenders with the option to accelerate the maturity of the amounts due under the Senior Credit Agreement, which was $44.7 million as of December 31, 2022. Should the lenders accelerate the maturity of the amounts due under the Senior Credit Agreement, the Company would not have sufficient cash on hand or available liquidity to repay the outstanding debt. These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern.

CY2022

us-gaap

Substantial Doubt About Going Concern Within One Year

SubstantialDoubtAboutGoingConcernWithinOneYear

true

CY2021Q4

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation

19305000

CY2022

atnx

Business Combination Measurement Period Adjustments Increase In In Process Research And Development

BusinessCombinationMeasurementPeriodAdjustmentsIncreaseInInProcessResearchAndDevelopment

1400000

atnx

Business Combination Measurement Period Adjustments Decrease In Deferred Tax Liability

BusinessCombinationMeasurementPeriodAdjustmentsDecreaseInDeferredTaxLiability

200000

atnx

Business Combination Measurement Period Adjustments Decrease In Goodwill

BusinessCombinationMeasurementPeriodAdjustmentsDecreaseInGoodwill

1600000

CY2022

us-gaap

Use Of Estimates

UseOfEstimates

Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in clinical research accruals, chargebacks, measurement of acquired assets and assumed liabilities in business combinations, provision for credit losses, inventory reserves, deferred income taxes, the estimated useful life and recoverability of long-lived assets, contingent consideration, accounting for debt extinguishment and the royalty financing liability, and the valuation of stock-based awards and other items as appropriate. Actual results could differ from those estimates.

CY2022

us-gaap

Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

900000

CY2021

us-gaap

Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

100000

CY2022Q4

us-gaap

Inventory Adjustments

InventoryAdjustments

2900000

CY2021Q4

us-gaap

Inventory Adjustments

InventoryAdjustments

6000000.0

CY2021Q4

us-gaap

Furniture And Fixtures Gross

FurnitureAndFixturesGross

223000

CY2022Q4

us-gaap

Capitalized Computer Software Gross

CapitalizedComputerSoftwareGross

2589000

CY2021

us-gaap

Number Of Operating Segments

NumberOfOperatingSegments

3

CY2022

us-gaap

Number Of Reporting Units

NumberOfReportingUnits

2

CY2021

us-gaap

Goodwill Impairment Loss

GoodwillImpairmentLoss

67700000

CY2022Q4

us-gaap

Goodwill

0

CY2021Q4

us-gaap

Goodwill

0

CY2021

us-gaap

Impairment Of Long Lived Assets To Be Disposed Of

ImpairmentOfLongLivedAssetsToBeDisposedOf

1700000

CY2022

us-gaap

Impairment Of Long Lived Assets To Be Disposed Of

ImpairmentOfLongLivedAssetsToBeDisposedOf

1800000

CY2022

atnx

Impairment Of Continuing Operations

ImpairmentOfContinuingOperations

100000

CY2022

atnx

Impairment Of Discontinued Operations

ImpairmentOfDiscontinuedOperations

1700000

CY2022Q4

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation

5718000

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

CY2022

us-gaap

Income Tax Examination Penalties And Interest Expense

IncomeTaxExaminationPenaltiesAndInterestExpense

0

CY2022

us-gaap

Concentration Risk Credit Risk

ConcentrationRiskCreditRisk

Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and short-term investments. The Company deposits its cash equivalents in interest-bearing money market accounts and certificates of deposit and invests in highly liquid U.S. Treasury notes, commercial paper, and corporate bonds. The Company deposits its cash with multiple financial institutions. Cash balances exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility, and research and development facility in China, and therefore is subject to foreign currency fluctuation and regulatory uncertainties.

CY2022

us-gaap

Income Loss From Discontinued Operations Net Of Tax

IncomeLossFromDiscontinuedOperationsNetOfTax

-5448000

CY2021

us-gaap

Income Loss From Discontinued Operations Net Of Tax

IncomeLossFromDiscontinuedOperationsNetOfTax

-41682000

CY2022Q4

us-gaap

Assets Of Disposal Group Including Discontinued Operation

AssetsOfDisposalGroupIncludingDiscontinuedOperation

7308000

CY2021Q4

us-gaap

Assets Of Disposal Group Including Discontinued Operation

AssetsOfDisposalGroupIncludingDiscontinuedOperation

72528000

CY2021

us-gaap

Business Acquisitions Pro Forma Revenue

BusinessAcquisitionsProFormaRevenue

95369000

CY2021

us-gaap

Business Acquisitions Pro Forma Net Income Loss

BusinessAcquisitionsProFormaNetIncomeLoss

-198641000

CY2022Q4

us-gaap

Inventory Raw Materials And Purchased Parts Net Of Reserves

InventoryRawMaterialsAndPurchasedPartsNetOfReserves

5703000

CY2021Q4

us-gaap

Inventory Raw Materials And Purchased Parts Net Of Reserves

InventoryRawMaterialsAndPurchasedPartsNetOfReserves

2959000

CY2022Q4

us-gaap

Inventory Work In Process Net Of Reserves

InventoryWorkInProcessNetOfReserves

69000

CY2021Q4

us-gaap

Inventory Work In Process Net Of Reserves

InventoryWorkInProcessNetOfReserves

12000

CY2022Q4

us-gaap

Inventory Finished Goods Net Of Reserves

InventoryFinishedGoodsNetOfReserves

36882000

CY2021Q4

us-gaap

Inventory Finished Goods Net Of Reserves

InventoryFinishedGoodsNetOfReserves

20097000

CY2022Q4

us-gaap

Inventory Net

InventoryNet

42654000

CY2021Q4

us-gaap

Inventory Net

InventoryNet

23068000

CY2022Q4

us-gaap

Machinery And Equipment Gross

MachineryAndEquipmentGross

2685000

CY2021Q4

us-gaap

Machinery And Equipment Gross

MachineryAndEquipmentGross

2636000

CY2022Q4

us-gaap

Furniture And Fixtures Gross

FurnitureAndFixturesGross

75000

CY2021Q4

us-gaap

Capitalized Computer Software Gross

CapitalizedComputerSoftwareGross

3714000

CY2022Q4

us-gaap

Leasehold Improvements Gross

LeaseholdImprovementsGross

690000

CY2021Q4

us-gaap

Leasehold Improvements Gross

LeaseholdImprovementsGross

1192000

CY2022Q4

us-gaap

Construction In Progress Gross

ConstructionInProgressGross

238000

CY2021Q4

us-gaap

Construction In Progress Gross

ConstructionInProgressGross

147000

CY2022Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

6277000

CY2021Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

7912000

CY2022Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

4453000

CY2021Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

4721000

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

1824000

CY2021Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3191000

CY2022

us-gaap

Depreciation

1100000

CY2021

us-gaap

Depreciation

1400000

CY2020Q4

us-gaap

Goodwill

38891000

CY2021

us-gaap

Goodwill Acquired During Period

GoodwillAcquiredDuringPeriod

28711000

CY2021

us-gaap

Goodwill Foreign Currency Translation Gain Loss

GoodwillForeignCurrencyTranslationGainLoss

-77000

CY2021

us-gaap

Goodwill Impairment Loss

GoodwillImpairmentLoss

67679000

CY2022

us-gaap

Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss

IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss

-10000

CY2022

us-gaap

Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss

IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss

-10000

CY2022Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

79802000

CY2022Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

7612000

CY2022

us-gaap

Impairment Of Intangible Assets Excluding Goodwill

ImpairmentOfIntangibleAssetsExcludingGoodwill

78000

CY2022Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

72112000

CY2021

us-gaap

Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss

IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss

-10000

CY2021

us-gaap

Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss

IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss

-10000

CY2021Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

83577000

CY2021Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

9941000

CY2021

us-gaap

Impairment Of Intangible Assets Excluding Goodwill

ImpairmentOfIntangibleAssetsExcludingGoodwill

1740000

CY2021Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

71896000

CY2022

us-gaap

Acquired Finite Lived Intangible Assets Weighted Average Useful Life

AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife

P6Y7D

CY2022

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

1200000

CY2021

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

1800000

CY2022Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Next Twelve Months

FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

1803000

CY2022Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Two

FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

1476000

CY2022Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Three

FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

1410000

CY2022Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Four

FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

822000

CY2022Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

627000

CY2022Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense After Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

434000

CY2022Q4

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

6572000

CY2022

us-gaap

Number Of Reporting Units

NumberOfReportingUnits

2

CY2022Q4

atnx

Fair Value Liabilities Level2 To Level1 Transfers Amount1

FairValueLiabilitiesLevel2ToLevel1TransfersAmount1

0

CY2021Q4

atnx

Fair Value Liabilities Level2 To Level1 Transfers Amount1

FairValueLiabilitiesLevel2ToLevel1TransfersAmount1

0

CY2022Q4

atnx

Fair Value Liabilities Level1 To Level2 Transfers Amount1

FairValueLiabilitiesLevel1ToLevel2TransfersAmount1

0

CY2021Q4

atnx

Fair Value Liabilities Level1 To Level2 Transfers Amount1

FairValueLiabilitiesLevel1ToLevel2TransfersAmount1

0

CY2022Q4

atnx

Fair Value Assets Level1 To Level2 Transfers Amount1

FairValueAssetsLevel1ToLevel2TransfersAmount1

0

CY2021Q4

atnx

Fair Value Assets Level1 To Level2 Transfers Amount1

FairValueAssetsLevel1ToLevel2TransfersAmount1

0

CY2022Q4

atnx

Fair Value Assets Level2 To Level1 Transfers Amount1

FairValueAssetsLevel2ToLevel1TransfersAmount1

0

CY2021Q4

atnx

Fair Value Assets Level2 To Level1 Transfers Amount1

FairValueAssetsLevel2ToLevel1TransfersAmount1

0

CY2022

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

0

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

0

CY2022

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

0

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

0

CY2022Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

20272000

CY2022Q4

us-gaap

Liabilities Fair Value Disclosure

LiabilitiesFairValueDisclosure

106631000

CY2021Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

30590000

CY2021Q4

us-gaap

Liabilities Fair Value Disclosure

LiabilitiesFairValueDisclosure

24076000

CY2022

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3

0

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3

0

CY2022

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3

0

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3

0

CY2022Q4

atnx

Accrued Selling Fees Rebates And Royalties

AccruedSellingFeesRebatesAndRoyalties

11290000

CY2021Q4

atnx

Accrued Selling Fees Rebates And Royalties

AccruedSellingFeesRebatesAndRoyalties

6890000

CY2022Q4

atnx

Accrued Clinical Expenses Current

AccruedClinicalExpensesCurrent

8581000

CY2021Q4

atnx

Accrued Clinical Expenses Current

AccruedClinicalExpensesCurrent

3116000

CY2022Q4

us-gaap

Employee Related Liabilities Current

EmployeeRelatedLiabilitiesCurrent

5868000

CY2021Q4

us-gaap

Employee Related Liabilities Current

EmployeeRelatedLiabilitiesCurrent

1827000

CY2022Q4

atnx

Accrued Inventory Purchases Current

AccruedInventoryPurchasesCurrent

3555000

CY2021Q4

atnx

Accrued Inventory Purchases Current

AccruedInventoryPurchasesCurrent

4218000

CY2022Q4

us-gaap

Deferred Revenue Current

DeferredRevenueCurrent

2823000

CY2021Q4

us-gaap

Deferred Revenue Current

DeferredRevenueCurrent

2798000

CY2022Q4

us-gaap

Accrued Income Taxes Current

AccruedIncomeTaxesCurrent

1750000

CY2021Q4

us-gaap

Accrued Income Taxes Current

AccruedIncomeTaxesCurrent

1800000

CY2022Q4

atnx

Accrued Operating Expenses Current

AccruedOperatingExpensesCurrent

1469000

CY2021Q4

atnx

Accrued Operating Expenses Current

AccruedOperatingExpensesCurrent

2647000

CY2022Q4

us-gaap

Accrued Royalties Current

AccruedRoyaltiesCurrent

29000

CY2021Q4

us-gaap

Accrued Royalties Current

AccruedRoyaltiesCurrent

116000

CY2021Q4

atnx

Accrued Interest

AccruedInterest

266000

CY2022Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

35365000

CY2021Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

23678000

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

300000

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

-10600000

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

-93979000

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

-153505000

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Foreign

IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

-4649000

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Foreign

IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

-17453000

CY2022

atnx

Income Loss From Continuing And Discontinuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingAndDiscontinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-98628000

CY2021

atnx

Income Loss From Continuing And Discontinuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingAndDiscontinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-170958000

CY2022

atnx

Income Loss From Discontinuing Operations Before Income Taxes Domestic

IncomeLossFromDiscontinuingOperationsBeforeIncomeTaxesDomestic

8922000

CY2021

atnx

Income Loss From Discontinuing Operations Before Income Taxes Domestic

IncomeLossFromDiscontinuingOperationsBeforeIncomeTaxesDomestic

-30094000

CY2022

atnx

Income Loss From Discontinuing Operations Before Income Taxes Foreign

IncomeLossFromDiscontinuingOperationsBeforeIncomeTaxesForeign

-13176000

CY2021

atnx

Income Loss From Discontinuing Operations Before Income Taxes Foreign

IncomeLossFromDiscontinuingOperationsBeforeIncomeTaxesForeign

-11588000

CY2022

atnx

Income Loss From Discontinuing Operations Before Income Taxes

IncomeLossFromDiscontinuingOperationsBeforeIncomeTaxes

-4254000

CY2021

atnx

Income Loss From Discontinuing Operations Before Income Taxes

IncomeLossFromDiscontinuingOperationsBeforeIncomeTaxes

-41682000

CY2022

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

3000

CY2021

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

13000

CY2022

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

344000

CY2021

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

234000

CY2022

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

347000

CY2021

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

247000

CY2022

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

-33522000

CY2021

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

8917000

CY2022

us-gaap

Deferred State And Local Income Tax Expense Benefit

DeferredStateAndLocalIncomeTaxExpenseBenefit

-452000

CY2021

us-gaap

Deferred State And Local Income Tax Expense Benefit

DeferredStateAndLocalIncomeTaxExpenseBenefit

-246000

CY2022

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

-211000

CY2021

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

229000

CY2022

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-34185000

CY2021

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

8900000

CY2022

atnx

Valuation Allowance Deferred Tax Asset Change In Amount Continuing Operations

ValuationAllowanceDeferredTaxAssetChangeInAmountContinuingOperations

-34185000

CY2021

atnx

Valuation Allowance Deferred Tax Asset Change In Amount Continuing Operations

ValuationAllowanceDeferredTaxAssetChangeInAmountContinuingOperations

19751000

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

347000

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

-10604000

CY2022

atnx

Current Foreign Tax Expense Benefit Discontinuing Operations

CurrentForeignTaxExpenseBenefitDiscontinuingOperations

1194000

CY2022

atnx

Current Income Tax Expense Benefit Discontinuing Operations

CurrentIncomeTaxExpenseBenefitDiscontinuingOperations

1194000

CY2022

atnx

Deferred Federal Income Tax Expense Benefit Discontinuing Operations

DeferredFederalIncomeTaxExpenseBenefitDiscontinuingOperations

-356000

CY2021

atnx

Deferred Federal Income Tax Expense Benefit Discontinuing Operations

DeferredFederalIncomeTaxExpenseBenefitDiscontinuingOperations

-2818000

CY2022

atnx

Deferred State And Local Income Tax Expense Benefit Discontinuing Operations

DeferredStateAndLocalIncomeTaxExpenseBenefitDiscontinuingOperations

34000

CY2021

atnx

Deferred State And Local Income Tax Expense Benefit Discontinuing Operations

DeferredStateAndLocalIncomeTaxExpenseBenefitDiscontinuingOperations

-88000

CY2022

atnx

Deferred Foreign Income Tax Expense Benefit Discontinuing Operations

DeferredForeignIncomeTaxExpenseBenefitDiscontinuingOperations

3303000

CY2021

atnx

Deferred Foreign Income Tax Expense Benefit Discontinuing Operations

DeferredForeignIncomeTaxExpenseBenefitDiscontinuingOperations

29000

CY2022

atnx

Deferred Income Tax Expense Benefit Discontinuing Operations

DeferredIncomeTaxExpenseBenefitDiscontinuingOperations

2981000

CY2021

atnx

Deferred Income Tax Expense Benefit Discontinuing Operations

DeferredIncomeTaxExpenseBenefitDiscontinuingOperations

-2877000

CY2022

atnx

Valuation Allowance Deferred Tax Asset Change In Amount Discontinuing Operations

ValuationAllowanceDeferredTaxAssetChangeInAmountDiscontinuingOperations

2981000

CY2021

atnx

Valuation Allowance Deferred Tax Asset Change In Amount Discontinuing Operations

ValuationAllowanceDeferredTaxAssetChangeInAmountDiscontinuingOperations

-2877000

CY2022

atnx

Income Tax Expense Benefit Discontinuing Operations

IncomeTaxExpenseBenefitDiscontinuingOperations

1194000

CY2022

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2021

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2022

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.004

CY2021

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.004

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential

EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential

-0.001

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.347

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

0.116

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent

EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent

-0.007

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent

EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent

-0.006

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses

-0.051

CY2022

atnx

Effective Income Tax Rate Reconciliation Section Three Eight Two Limitation

EffectiveIncomeTaxRateReconciliationSectionThreeEightTwoLimitation

0.078

CY2021

atnx

Effective Income Tax Rate Reconciliation Section Three Eight Two Limitation

EffectiveIncomeTaxRateReconciliationSectionThreeEightTwoLimitation

-0.134

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

0.002

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

-0.062

CY2022

atnx

Effective Income Tax Rate Reconciliation Foreign Tax Withholdings

EffectiveIncomeTaxRateReconciliationForeignTaxWithholdings

-0.003

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Tax Contingencies Foreign

EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign

0.064

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.005

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.014

CY2022

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

-0.004

CY2021

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.062

CY2022Q4

us-gaap

Deferred Tax Assets Goodwill And Intangible Assets

DeferredTaxAssetsGoodwillAndIntangibleAssets

12042000

CY2021Q4

us-gaap

Deferred Tax Assets Goodwill And Intangible Assets

DeferredTaxAssetsGoodwillAndIntangibleAssets

11675000

CY2022Q4

atnx

Deferred Tax Assets Section One Seven Four

DeferredTaxAssetsSectionOneSevenFour

8993000

CY2022Q4

us-gaap

Deferred Tax Assets Property Plant And Equipment

DeferredTaxAssetsPropertyPlantAndEquipment

39000

CY2021Q4

us-gaap

Deferred Tax Assets Property Plant And Equipment

DeferredTaxAssetsPropertyPlantAndEquipment

39000

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

7935000

CY2021Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

7743000

CY2022Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

102909000

CY2021Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

106017000

CY2022Q4

us-gaap

Deferred Tax Assets Capital Loss Carryforwards

DeferredTaxAssetsCapitalLossCarryforwards

6000000

CY2022Q4

us-gaap

Deferred Tax Asset Interest Carryforward

DeferredTaxAssetInterestCarryforward

12739000

CY2021Q4

us-gaap

Deferred Tax Asset Interest Carryforward

DeferredTaxAssetInterestCarryforward

10580000

CY2022Q4

atnx

Deferred Tax Assets Royalty Monetization

DeferredTaxAssetsRoyaltyMonetization

17964000

CY2022Q4

us-gaap

Deferred Tax Assets Tax Credit Carryforwards

DeferredTaxAssetsTaxCreditCarryforwards

1129000

CY2021Q4

us-gaap

Deferred Tax Assets Tax Credit Carryforwards

DeferredTaxAssetsTaxCreditCarryforwards

956000

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves

10509000

CY2021Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves

9411000

CY2022Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

180259000

CY2021Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

146421000

CY2022Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

168622000

CY2021Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

134439000

CY2022Q4

us-gaap

Deferred Tax Assets Net

DeferredTaxAssetsNet

11637000

CY2021Q4

us-gaap

Deferred Tax Assets Net

DeferredTaxAssetsNet

11982000

CY2022Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssets

13388000

CY2021Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssets

13341000

CY2021Q4

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

392000

CY2022Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

13388000

CY2021Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

13733000

CY2022Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

1751000

CY2021Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

1751000

CY2022Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards Domestic

DeferredTaxAssetsOperatingLossCarryforwardsDomestic

438900000

CY2022Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards State And Local

DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal

94600000

CY2022Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards Foreign

DeferredTaxAssetsOperatingLossCarryforwardsForeign

28200000

CY2022

us-gaap

Valuation Allowance Deferred Tax Asset Change In Amount

ValuationAllowanceDeferredTaxAssetChangeInAmount

34200000

CY2021

us-gaap

Valuation Allowance Deferred Tax Asset Change In Amount

ValuationAllowanceDeferredTaxAssetChangeInAmount

-13100000

CY2022Q4

us-gaap

Liability For Uncertain Tax Positions Current

LiabilityForUncertainTaxPositionsCurrent

0

CY2021Q4

us-gaap

Liability For Uncertain Tax Positions Current

LiabilityForUncertainTaxPositionsCurrent

0

CY2022

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

0

CY2021

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

0

CY2021

atnx

Net Operating Loss Limitation Amount

NetOperatingLossLimitationAmount

72200000

CY2021

atnx

Research And Development Credit Limitation Amount

ResearchAndDevelopmentCreditLimitationAmount

9300000

CY2022Q4

us-gaap

Secured Debt Current

SecuredDebtCurrent

36989000

CY2021Q4

us-gaap

Secured Debt Current

SecuredDebtCurrent

45938000

CY2022Q4

us-gaap

Finance Lease Liability Current

FinanceLeaseLiabilityCurrent

138000

CY2021Q4

us-gaap

Finance Lease Liability Current

FinanceLeaseLiabilityCurrent

138000

CY2022Q4

us-gaap

Operating Lease Liability Current

OperatingLeaseLiabilityCurrent

2087000

CY2021Q4

us-gaap

Operating Lease Liability Current

OperatingLeaseLiabilityCurrent

2478000

CY2022Q4

us-gaap

Finance Lease Liability Noncurrent

FinanceLeaseLiabilityNoncurrent

93000

CY2021Q4

us-gaap

Finance Lease Liability Noncurrent

FinanceLeaseLiabilityNoncurrent

207000

CY2022Q4

us-gaap

Operating Lease Liability Noncurrent

OperatingLeaseLiabilityNoncurrent

3051000

CY2021Q4

us-gaap

Operating Lease Liability Noncurrent

OperatingLeaseLiabilityNoncurrent

4494000

CY2022Q4

atnx

Debt Current And Non Current

DebtCurrentAndNonCurrent

129103000

CY2021Q4

atnx

Debt Current And Non Current

DebtCurrentAndNonCurrent

148655000

CY2022

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-3100000

CY2022

us-gaap

Operating Lease Cost

OperatingLeaseCost

2232000

CY2021

us-gaap

Operating Lease Cost

OperatingLeaseCost

2498000

CY2022

us-gaap

Finance Lease Right Of Use Asset Amortization

FinanceLeaseRightOfUseAssetAmortization

114000

CY2021

us-gaap

Finance Lease Right Of Use Asset Amortization

FinanceLeaseRightOfUseAssetAmortization

114000

CY2022

us-gaap

Finance Lease Interest Expense

FinanceLeaseInterestExpense

34000

CY2021

us-gaap

Finance Lease Interest Expense

FinanceLeaseInterestExpense

46000

CY2022

us-gaap

Lease Cost

LeaseCost

2380000

CY2021

us-gaap

Lease Cost

LeaseCost

2658000

CY2022Q4

atnx

Finance Lease Right Of Use Asset Gross

FinanceLeaseRightOfUseAssetGross

515000

CY2021Q4

atnx

Finance Lease Right Of Use Asset Gross

FinanceLeaseRightOfUseAssetGross

515000

CY2022Q4

atnx

Finance Lease Right Of Use Asset Accumulated Amortization Net

FinanceLeaseRightOfUseAssetAccumulatedAmortizationNet

315000

CY2021Q4

atnx

Finance Lease Right Of Use Asset Accumulated Amortization Net

FinanceLeaseRightOfUseAssetAccumulatedAmortizationNet

200000

CY2022Q4

us-gaap

Finance Lease Right Of Use Asset

FinanceLeaseRightOfUseAsset

200000

CY2021Q4

us-gaap

Finance Lease Right Of Use Asset

FinanceLeaseRightOfUseAsset

315000

CY2022Q4

us-gaap

Finance Lease Liability Current

FinanceLeaseLiabilityCurrent

138000

CY2021Q4

us-gaap

Finance Lease Liability Current

FinanceLeaseLiabilityCurrent

138000

CY2022Q4

us-gaap

Finance Lease Liability Noncurrent

FinanceLeaseLiabilityNoncurrent

93000

CY2021Q4

us-gaap

Finance Lease Liability Noncurrent

FinanceLeaseLiabilityNoncurrent

207000

CY2022Q4

atnx

Finance Lease Obligations

FinanceLeaseObligations

231000

CY2021Q4

atnx

Finance Lease Obligations

FinanceLeaseObligations

345000

CY2022Q4

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P2Y11M15D

CY2021Q4

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P3Y9M

CY2022Q4

us-gaap

Finance Lease Weighted Average Remaining Lease Term1

FinanceLeaseWeightedAverageRemainingLeaseTerm1

P1Y2M15D

CY2021Q4

us-gaap

Finance Lease Weighted Average Remaining Lease Term1

FinanceLeaseWeightedAverageRemainingLeaseTerm1

P1Y4M9D

CY2022Q4

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.131

CY2021Q4

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.130

CY2022Q4

us-gaap

Finance Lease Weighted Average Discount Rate Percent

FinanceLeaseWeightedAverageDiscountRatePercent

0.079

CY2021Q4

us-gaap

Finance Lease Weighted Average Discount Rate Percent

FinanceLeaseWeightedAverageDiscountRatePercent

0.056

CY2022

us-gaap

Operating Lease Payments

OperatingLeasePayments

2623000

CY2021

us-gaap

Operating Lease Payments

OperatingLeasePayments

2830000

CY2022

us-gaap

Finance Lease Interest Payment On Liability

FinanceLeaseInterestPaymentOnLiability

113000

CY2021

us-gaap

Finance Lease Interest Payment On Liability

FinanceLeaseInterestPaymentOnLiability

101000

CY2022

us-gaap

Finance Lease Principal Payments

FinanceLeasePrincipalPayments

34000

CY2021

us-gaap

Finance Lease Principal Payments

FinanceLeasePrincipalPayments

46000

CY2022

us-gaap

Right Of Use Asset Obtained In Exchange For Finance Lease Liability

RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability

18000

CY2021

us-gaap

Right Of Use Asset Obtained In Exchange For Finance Lease Liability

RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability

89000

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Next Twelve Months

LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

2238000

CY2022Q4

us-gaap

Finance Lease Liability Payments Due Next Twelve Months

FinanceLeaseLiabilityPaymentsDueNextTwelveMonths

147000

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Two

LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

2034000

CY2022Q4

us-gaap

Finance Lease Liability Payments Due Year Two

FinanceLeaseLiabilityPaymentsDueYearTwo

110000

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Three

LesseeOperatingLeaseLiabilityPaymentsDueYearThree

1472000

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Four

LesseeOperatingLeaseLiabilityPaymentsDueYearFour

347000

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Five

LesseeOperatingLeaseLiabilityPaymentsDueYearFive

131000

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due

LesseeOperatingLeaseLiabilityPaymentsDue

6222000

CY2022Q4

us-gaap

Finance Lease Liability Payments Due

FinanceLeaseLiabilityPaymentsDue

257000

CY2022Q4

us-gaap

Lessee Operating Lease Liability Undiscounted Excess Amount

LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

1084000

CY2022Q4

us-gaap

Finance Lease Liability Undiscounted Excess Amount

FinanceLeaseLiabilityUndiscountedExcessAmount

26000

CY2022Q4

us-gaap

Operating Lease Liability

OperatingLeaseLiability

5138000

CY2022Q4

us-gaap

Finance Lease Liability

FinanceLeaseLiability

231000

CY2022Q4

us-gaap

Operating Lease Liability Current

OperatingLeaseLiabilityCurrent

2087000

CY2022Q4

us-gaap

Finance Lease Liability Current

FinanceLeaseLiabilityCurrent

138000

CY2022Q4

us-gaap

Operating Lease Liability Noncurrent

OperatingLeaseLiabilityNoncurrent

3051000

CY2022Q4

us-gaap

Finance Lease Liability Noncurrent

FinanceLeaseLiabilityNoncurrent

93000

CY2022

atnx

Contingent Consideration Milestone Term

ContingentConsiderationMilestoneTerm

The Company expects that these milestones will be achieved at varying times between 2023 and 2028.

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award

ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward

73030

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased

ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased

6.60

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

632912

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

179.00

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P4Y10M17D

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

106395

CY2022

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

13.00

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

102536

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

195.80

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

636771

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

148.80

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P4Y8M1D

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

468834

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

174.40

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

P4Y8M26D

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

13.00

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

75.40

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate

0.68

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate

0.68

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0301

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0129

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y2M12D

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y2M12D

CY2022

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

6326000

CY2021

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

9207000

CY2022

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

6326000

CY2021

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

9207000

CY2022

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

1538356

CY2021

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

698860

CY2021

us-gaap

Net Income Loss

NetIncomeLoss

-199768000

CY2022

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

4468000

CY2021

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

5003000

CY2022

us-gaap

Number Of Operating Segments

NumberOfOperatingSegments

2

CY2022

us-gaap

Revenue From Contract With Customer Excluding Assessed Tax

RevenueFromContractWithCustomerExcludingAssessedTax

102821000

CY2021

us-gaap

Revenue From Contract With Customer Excluding Assessed Tax

RevenueFromContractWithCustomerExcludingAssessedTax

95369000

CY2022

us-gaap

Revenue From Contract With Customer Excluding Assessed Tax

RevenueFromContractWithCustomerExcludingAssessedTax

102821000

CY2021

us-gaap

Revenue From Contract With Customer Excluding Assessed Tax

RevenueFromContractWithCustomerExcludingAssessedTax

95369000

CY2022

us-gaap

Net Income Loss

NetIncomeLoss

-103427000

CY2022Q4

us-gaap

Assets

204055000

CY2021Q4

us-gaap

Assets

267448000

CY2022

us-gaap

Revenue From Contract With Customer Excluding Assessed Tax

RevenueFromContractWithCustomerExcludingAssessedTax

102821000

CY2021

us-gaap

Revenue From Contract With Customer Excluding Assessed Tax

RevenueFromContractWithCustomerExcludingAssessedTax

95369000

CY2022

atnx

Contract With Customer Liability Commercial Milestones Revenue Recognized

ContractWithCustomerLiabilityCommercialMilestonesRevenueRecognized

2500000

CY2021

atnx

Contract With Customer Liability Commercial Milestones Revenue Recognized

ContractWithCustomerLiabilityCommercialMilestonesRevenueRecognized

25000000.0

CY2022Q4

atnx

Sales Discount Goods Percentage

SalesDiscountGoodsPercentage

0.023

CY2022

us-gaap

Revenue From Contract With Customer Excluding Assessed Tax

RevenueFromContractWithCustomerExcludingAssessedTax

102821000

CY2021

us-gaap

Revenue From Contract With Customer Excluding Assessed Tax

RevenueFromContractWithCustomerExcludingAssessedTax

95369000

CY2022Q4

us-gaap

Accounts Receivable Gross Current

AccountsReceivableGrossCurrent

67011000

CY2021Q4

us-gaap

Accounts Receivable Gross Current

AccountsReceivableGrossCurrent

54716000

CY2022Q4

atnx

Chargebacks And Other Deductions Current

ChargebacksAndOtherDeductionsCurrent

29470000

CY2021Q4

atnx

Chargebacks And Other Deductions Current

ChargebacksAndOtherDeductionsCurrent

22869000

CY2022Q4

us-gaap

Allowance For Doubtful Accounts Receivable Current

AllowanceForDoubtfulAccountsReceivableCurrent

9676000

CY2021Q4

us-gaap

Allowance For Doubtful Accounts Receivable Current

AllowanceForDoubtfulAccountsReceivableCurrent

9069000

CY2022Q4

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

27865000

CY2021Q4

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

22778000

CY2022Q4

us-gaap

Contract With Customer Liability Current

ContractWithCustomerLiabilityCurrent

2823000

CY2021Q4

us-gaap

Contract With Customer Liability Current

ContractWithCustomerLiabilityCurrent

2798000

CY2022Q4

us-gaap

Contract With Customer Liability

ContractWithCustomerLiability

2823000

CY2021Q4

us-gaap

Contract With Customer Liability

ContractWithCustomerLiability

2798000

CY2022Q4

us-gaap

Accounts Receivable Gross Current

AccountsReceivableGrossCurrent

67011000

CY2022Q4

atnx

Chargebacks And Other Deductions Current

ChargebacksAndOtherDeductionsCurrent

29470000

CY2022Q4

us-gaap

Allowance For Doubtful Accounts Receivable Current

AllowanceForDoubtfulAccountsReceivableCurrent

9676000

CY2022Q4

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

27865000

CY2021Q4

us-gaap

Accounts Receivable Gross Current

AccountsReceivableGrossCurrent

54716000

CY2021Q4

atnx

Chargebacks And Other Deductions Current

ChargebacksAndOtherDeductionsCurrent

22869000

CY2021Q4

us-gaap

Allowance For Doubtful Accounts Receivable Current

AllowanceForDoubtfulAccountsReceivableCurrent

9069000

CY2021Q4

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

22778000

CY2022

us-gaap

Operating Lease Expense

OperatingLeaseExpense

1000000.0

CY2021

us-gaap

Operating Lease Expense

OperatingLeaseExpense

1000000.0

CY2022

atnx

Operating Lease Amount Obligated To Spent

OperatingLeaseAmountObligatedToSpent

100000000.0

CY2022

atnx

Operating Lease Additional Amount Obligated To Spent

OperatingLeaseAdditionalAmountObligatedToSpent

100000000.0

CY2022Q4

atnx

Number Of Permanent Employees Commited To Hiring

NumberOfPermanentEmployeesCommitedToHiring

250

CY2022

atnx

Project Completion Term

ProjectCompletionTerm

P5Y

CY2022Q4

atnx

Number Of Permanent Employees Hired

NumberOfPermanentEmployeesHired

36

CY2022

atnx

Lease Expiration Terms

LeaseExpirationTerms

expire at various times through 2025

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Next Twelve Months

LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

2238000

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Two

LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

2034000

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Three

LesseeOperatingLeaseLiabilityPaymentsDueYearThree

1472000

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Four

LesseeOperatingLeaseLiabilityPaymentsDueYearFour

347000

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due After Year Five

LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

131000

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due

LesseeOperatingLeaseLiabilityPaymentsDue

6222000

CY2022

atnx

Loss Contingency Number Of Law Suits

LossContingencyNumberOfLawSuits

2

Name	View Source	Status
0000950170-23-008734-index-headers.html	Edgar Link	pending
0000950170-23-008734-index.html	Edgar Link	pending
0000950170-23-008734.txt	Edgar Link	pending
0000950170-23-008734-xbrl.zip	Edgar Link	pending
atnx-20221231.htm	Edgar Link	pending
atnx-20221231.xsd	Edgar Link	pending
atnx-ex10_13.htm	Edgar Link	pending
atnx-ex10_14.htm	Edgar Link	pending
atnx-ex10_67.htm	Edgar Link	pending
atnx-ex21_1.htm	Edgar Link	pending
atnx-ex23_1.htm	Edgar Link	pending
atnx-ex31_1.htm	Edgar Link	pending
atnx-ex31_2.htm	Edgar Link	pending
atnx-ex32_1.htm	Edgar Link	pending
atnx-ex4_1.htm	Edgar Link	pending
atnx-ex4_7.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img103648461_0.jpg	Edgar Link	pending
img103648461_1.jpg	Edgar Link	pending
img103648461_2.jpg	Edgar Link	pending
img103648461_3.jpg	Edgar Link	pending
img118509878_0.jpg	Edgar Link	pending
img118509878_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
atnx-20221231_cal.xml	Edgar Link	unprocessable
atnx-20221231_pre.xml	Edgar Link	unprocessable
atnx-20221231_htm.xml	Edgar Link	completed
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
atnx-20221231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
atnx-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Athenex, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023008734 Filed on March 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission